

BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email info.bmjopen@bmj.com

BMJ Open

A Cohort Study of the Characteristics and Outcomes in Patients with COVID-19 and In-Hospital Cardiac Arrest

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2021-054943
Article Type:	Original research
Date Submitted by the Author:	06-Jul-2021
Complete List of Authors:	<p>Holm, Astrid; University of Gothenburg, Department of Molecular and Clinical Medicine Jerkeman, Matilda; University of Gothenburg, Department of Molecular and Clinical Medicine Sultanian, Pedram; University of Gothenburg, Department of Molecular and Clinical Medicine Lundgren, Peter; University of Gothenburg, Department of Molecular and Clinical Medicine; Kalmar County Hospital, Department of Internal Medicine Ravn-Fischer, Annica; University of Gothenburg, Department of Molecular and Clinical Medicine Israelsson, Johan; Kalmar County Hospital, Department of Internal Medicine; Linnaeus University, Faculty of Health and Life Sciences Giesecke, Jasna; Danderyd University Hospital Herlitz, Johan; University of Borås, Centre for Prehospital Research Rawshani, Araz; University of Gothenburg, Department of Molecular and Clinical Medicine</p>
Keywords:	COVID-19, CARDIOLOGY, Adult cardiology < CARDIOLOGY, Coronary heart disease < CARDIOLOGY

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

A Cohort Study of the Characteristics and Outcomes in Patients with COVID-19 and In-Hospital Cardiac Arrest

Astrid Holm, MD¹, Matilda Jerkeman, MD¹, Pedram Sultanian, MD¹, Peter Lundgren, MD, PhD^{1,3,7}, Annica Ravn-Fischer, MD, PhD, Docent¹, Johan Israelsson, PhD^{3,4}, Jasna Giesecke, RN⁵, Johan Herlitz, MD, PhD^{2,6}, Araz Rawshani, MD, PhD^{1,2}

Affiliations:

¹Department of Molecular and Clinical Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Sweden

²The Swedish Registry for Cardiopulmonary Resuscitation, Centre of Registries, Västra Götaland County, Sweden

³Department of Internal Medicine, Division of Cardiology, Kalmar County Hospital, Region Kalmar County, Sweden

⁴Faculty of Health and Life Sciences, Linnaeus University, Kalmar, Sweden

⁵RN, Lead CPR coordinator, Clinicum- Centre for clinical skills, interprofessional education and advanced medical simulation, Danderyd University Hospital, Stockholm, Sweden

⁶Prehospen – Centre for Prehospital Research, University of Borås, Borås, Sweden

⁷Region Västra Götaland, Sahlgrenska University Hospital, Department of Cardiology, Gothenburg, Sweden

Contact information:

Astrid Holm

Email: astrid.holm@gu.se

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1 Phone: +358 400707722

2

3

4 **Manuscript word count:** 3592

5

6 **Keywords:** COVID19, SARS-COV-2, Coronavirus, cardiac arrest, in-hospital cardiac arrest

7

1 Key Points

2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

2 **Question:** What are the Characteristics, causes and outcomes in patients with COVID-19 who
3 suffer an in-hospital cardiac arrest (IHCA)?

4 **Findings:** In the registry-based observational study we found that during pandemic peaks, up
5 to one fourth of all IHCAs are complicated by COVID-19, and these patients have halved
6 chance of survival.

7 **Meaning:** The survival rate of patients with COVID-19 associated IHCA is low with women
8 displaying the worst outcomes.

9 Abstract

10 **Objective:** We studied characteristics, survival, causes of cardiac arrest, conditions preceding
11 cardiac arrest, predictors of survival, and trends in the prevalence of COVID-19 among IHCA
12 cases. Data on characteristics and outcomes in patients with COVID-19 who suffer an in-
13 hospital cardiac arrest (IHCA) is scarce.

14 **Design and setting:** Registry-based observational study.

15 **Participants:** We studied all cases of IHCA receiving CPR (≥ 18 years of age) in the Swedish
16 Registry for Cardiopulmonary Resuscitation from 15/03/2020 to 31/12/2020. A total of 1613

1 patients were included and divided into the following groups: ongoing infection (**COVID+**;
2 n=182), no infection (**COVID-**; n=1062) and unknown/not assessed (**UNA**; n=369).

3 **Main outcomes and measures:** We studied monthly trends in proportions of COVID-19
4 associated IHCAs, causes of IHCA in relation to COVID-19 status, clinical conditions
5 preceding the cardiac arrest and predictors of survival.

6 **Results:** The rate of COVID+ patients suffering an IHCA increased to 23% during the first
7 pandemic wave (April), then abated to 3% in July, and then increased to 19% during the
8 second wave (December). Among COVID+ cases, 43% had respiratory insufficiency or
9 infection as the underlying cause of the cardiac arrest, compared to 18% among COVID-
10 cases. The most common clinical sign preceding cardiac arrest was hypoxia (57%) among
11 COVID+ cases. Odds ratio for 30-day survival for COVID+ cases was 0.50 (95% CI 0.33-
12 0.76) compared with COVID- cases. At the end of follow-up, 19% of COVID+ cases and
13 35.6% of COVID- cases had been discharged alive. Among COVID+ cases, 22% of men,
14 compared with 14% of women, were discharged alive.

15 **Conclusion:** During pandemic peaks, up to one fourth of all IHCAs are complicated by
16 COVID-19, and these patients have halved chance of survival, with women displaying the
17 worst outcomes.

1 Article Summary

2 Strengths and limitations of this study

- 3 • A major strength of our study is that it includes all IHCA in Sweden which were
4 reported to the Swedish Registry for Cardiopulmonary Resuscitation.
- 5 • The sample recorded in the Swedish Registry for Cardiopulmonary Resuscitation is
6 unbiased since all hospitals participate in the registry and all hospitals report data on
7 COVID-19 status
- 8 • A limitation is that we do not know the severity of the COVID-19 infection, and we
9 do not know if COVID-19 was the main reason for admission to hospital.
- 10 • Our study only includes IHCA receiving CPR which leaves out all other patients with
11 IHCA, e.g with a Do Not Attempt Resuscitation order.
- 12 • It is important to stress the fact that our regression model that included only COVID-
13 19 cases must be interpreted with caution due to the large number of predictors in the
14 model, which had relatively few patients.

1 Introduction

2 The COVID-19 pandemic has, as of May 1st 2021 infected over 159,000,000 persons and lead
3 to the demise of over 3,321,000 individuals(1).The Swedish Public Health Authority declared
4 on March 16th 2020 that community spread of COVID-19 had commenced, and COVID-19 is
5 now the third leading cause of death in Sweden(2, 3).

6 A recent study including over 5,000 critically ill patients with COVID-19 showed that in-
7 hospital cardiac arrest (IHCA) is common and associated with poor survival(4). An early
8 study from Wuhan also showed poor survival after IHCA among COVID-19 patients(5). We
9 recently studied IHCA in the Swedish Registry for Cardiopulmonary Resuscitation (SRCR)
10 and showed a 2.3-fold increase in 30-day mortality among cases with COVID-19 compared to
11 pre-pandemic cases and this was mainly driven by a 9-fold increase in mortality among
12 women with COVID-19. During the study period no case of IHCA with COVID-19 was
13 discharged alive from the hospital(6).

14 The current study expands our previous investigation, including more patients, longer follow-
15 up and emphasizes the causes of cardiac arrest in COVID-19, predictors of survival,
16 coexisting conditions, and trends in the prevalence of COVID-19 among IHCA cases.

1 **Methods**

2 **Data sources**

3 The study is a registry-based observational study with data obtained from the SRCR during
4 the time period 15/03/2020 to 31/12/2020.

5 The SRCR is a national quality registry and has included IHCA cases since 2005. The data is
6 collected by trained nurses who report patient data using a web-based protocol. The registry
7 has previously been described in detail(7). Vital status was obtained from the Swedish
8 Population Registry and the last day of follow up was 31/12/2020.

9 **Study population**

10 The study population included all patients ≥ 18 years of age suffering from IHCA and
11 receiving CPR throughout Sweden during the period 15/03/2020 to 31/12/2020. We used 15th
12 of March as the start date of the pandemic as the Swedish Public Health Authority declared on
13 March 16th 2020 that COVID-19 was community spread in Sweden(3). On 1st of April the
14 SRCR started collecting data about COVID-19 status, and retrospectively identified 60
15 patients with COVID-19 who suffered IHCA during March (they were included in the study).
16 Patients were divided into the following three groups: ongoing infection (COVID+; n=182),
17 no infection (COVID-; n=1062) and unknown/not assessed (UNA; n=369). COVID+ was

1
2
3
4 1 defined as patients registered with an ongoing COVID-19 infection, suspected ongoing
5
6
7 2 infection or patients with a recent infection(n=29).
8
9

10 3 **Variable definitions**

11
12
13
14 4 In SRCR a patient with cardiac arrest was defined as an unconscious patient with no or
15
16
17 5 abnormal breathing, in whom resuscitation or defibrillation was attempted. IHCA was defined
18
19
20 6 as cardiac arrest in patients admitted to the hospital.
21
22

23
24 7 With regards to previous coexisting conditions heart failure was defined as any heart failure
25
26
27 8 described before cardiac arrest. Kidney failure was defined as estimated glomerular filtration
28
29
30 9 rate (eGFR) below 60 ml/min/1.73 m², calculated using the highest creatinine before cardiac
31
32
33
34 10 arrest with Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula based
35
36
37 11 on sex, age and creatinine. The SRCR records data on the highest creatinine levels analyzed
38
39
40
41 12 up to six months prior to CA. Diabetes was defined as any diabetes diagnosis, regardless of
42
43
44 13 type. Cancer was defined as any previously known cancer. Acute myocardial infarction (MI)
45
46
47 14 was defined as an MI within 72 hours of CA. Previous myocardial infarction was defined as
48
49
50
51 15 MI occurring earlier than 72 hours preceding the CA.
52

53
54 16 Regarding clinical conditions one hour prior to CA, arrhythmia was defined as any
55
56
57
58 17 arrhythmia, hypoxia was defined as an oxygen saturation below 90%, hypotension was
59
60

1 defined as systolic blood pressure below 90 mmHg, seizure was defined as any seizure with
2 loss of consciousness, and heart failure was defined as any heart failure with pulmonary
3 edema or severe shortness of breath with rales.

4 A monitored ward was defined as a coronary care unit(CCU), an intensive care unit(ICU), an
5 operational room(OR), an emergency room(ER), an intermediate care unit(IMCU) or a
6 catheterization laboratory(Cath lab). A non-monitored ward was defined as a regular ward
7 (RW). All other wards were defined as other ward, e.g. outpatient lab, radiology department,
8 etc.

9 **Statistical analyses**

10 Patient characteristics are reported in means and medians, along with standard deviations and
11 interquartile ranges, respectively. The Kaplan-Meier estimator was used for defining survival
12 distributions; the log rank test was used to test for differences in survival.

13 Logistic regression was used to calculate odds ratios for 30-days survival. These models
14 assessed the association between COVID-19 status and 30-days survival, while adjusting for
15 age, sex and initial rhythm (shockable or non-shockable). Subgroup analyzes were done for
16 men, women, age ≥ 70 years, age < 70 years, heart failure, kidney failure, diabetes, myocardial
17 infarction and cancer.

1
2
3
4 1 In order to obtain estimates of overall survival, we used Cox proportional hazards model with
5
6
7 2 hours since CA as the time scale. The proportional hazards assumption was fulfilled for all
8
9
10 3 variables.

11
12
13
14 4 We used the MICE (Multiple Imputation By Chained Equations) algorithm to impute missing
15
16
17 5 values(8, 9) (Supplementary Figure 1). The imputed data set was used to calculate odds ratios
18
19
20
21 6 for 30-days survival in the overall group, as well as in COVID+ and COVID- cases. These
22
23
24 7 models included age, sex, initial rhythm, time to start of cardiopulmonary resuscitation
25
26
27 8 (CPR), time of CA, previous MI, location (other ward vs monitored, and non-monitored ward
28
29
30
31 9 vs monitored), heart failure, EKG monitoring, diabetes and acute MI.

32
33
34
35 10 Analyses were done in R (v. 4.0.3, R Foundation for Statistical Computing) using RStudio.

36
37
38
39 11 The study was approved by the Swedish Ethical Review Authority (ID 2020-02017).

40 41 42 43 12 **Patient and Public Involvement statement:**

44
45 13 No patients were involved.

46 47 48 49 50 51 14 **Results**

52
53 15 A total of 2,227 patients were enrolled in the SRCR between 01/01/2020 and 31/12/2020.

54
55
56 16 After excluding patients <18 years (n=68) and pre-pandemic cases (n=546), 1,613 cases

57
58
59
60 17 remained from 15/03/2020 to 31/12/2020 and constituted the final study population

1 (Supplementary Figure 2). There was a high rate of information on COVID-19 status during
2 the study period among patients registered in the registry (Supplementary Figure 3).

3 **Baseline characteristics**

4 The overall mean age was 70.8 years, and the proportion of women was 37.6%. At the end of
5 follow-up, 341 (32.7%) patients were alive. The mean age was similar in the three groups:
6 70.9 years among COVID+, 71.0 years among COVID– cases, and 70.2 years in cases with
7 UNA (Supplementary Figure 4). The proportion of women was also similar; 37.6% in
8 COVID+, 36.6% in COVID– and 41.0% in UNA cases.

9 A regular ward (RW) was the most common place of cardiac arrest in all 3 groups with rates
10 of 45.1% among COVID+, 44.1% among COVID– and 31.4% among UNA (Table 1). The
11 emergency room (ER) was the second most common location for COVID+ cases (15.9%).
12 The ER was the location of cardiac arrest in 17.6% of UNA cases and 13.1% for COVID–
13 cases.

14 Regarding comorbidities, acute myocardial infarction was observed in 12.0% of COVID+ and
15 23.6% of COVID– cases. Previous myocardial infarction was observed in 11.7% of COVID+,
16 20.8% of COVID– and 11.7% of UNA cases. The prevalence of heart failure, cancer and
17 diabetes was similar across all groups (Table 1).

1 Fewer cases among COVID+ individuals had a shockable rhythm (17.3%), compared with
2 COVID- (24.9%) and UNA (27.0%). Likewise, fewer cases among COVID+ (22.7%) were
3 defibrillated, compared with COVID- (31.5%) and UNA (32.8%). COVID+ cases were
4 ventilated in 54.8% of cases before rescue team arrival, as compared with 63.2% and 69.2%
5 in COVID- and UNA, respectively.

6 **Follow-up and crude survival**

7 Return of spontaneous circulation (ROSC) after initial resuscitation, was less common in
8 COVID+ cases, as compared with COVID- and UNA. Also, angiography, PCI, pacemaker
9 and ICD implantation post cardiac arrest were less common in COVID+ cases.
10 Survival at 30-days was 37.3% in COVID- patients, compared to 22.5% among COVID+
11 patients (Table 1), and 35.6% of COVID- patients were discharged alive, compared with
12 19.0% of COVID+ patients.

14 **Sex specific characteristics**

15 Acute myocardial infarction was observed in 21.2% of COVID+ women and 7.6% of
16 COVID+ men. Previous myocardial infarction was observed in 4.7% of COVID+ women and
17 16.2% of COVID+ men. The prevalence of previous stroke, renal failure, heart failure, cancer

1 and diabetes were similar among men and women, as was location at the time of cardiac
2 arrest. COVID+ men were more likely to have a shockable rhythm (20.8%) compared with
3 COVID+ women (11.5%) and to be defibrillated (26.4% in men vs 16.9% in women). In all,
4 22.2% of COVID+ men were discharged alive from hospital compared to 14.0% of COVID+
5 women (Supplementary Table 1).

6 **Monthly trends in COVID-19 associated IHCA**

7 In March, April and May 14%, 23% and 20% of patients suffering IHCA were COVID+ (data
8 from 16th March). The proportion of COVID+ cases diminished rapidly during June to July.
9 From September onwards the COVID+ cases increased again to reach 19% in December. In
10 Figure 1A additional details regarding monthly variations are presented.

1 Etiology of IHCA

2 The most common cause of IHCA among COVID+ was respiratory insufficiency (24%,
3 n=24). The second most common cause was sepsis or other infection (19%, n=19) among
4 COVID+. Respiratory insufficiency and sepsis/other infection were less common in the other
5 groups (Figure 1B), which instead displayed higher rates of acute myocardial infarction.

6 Clinical conditions one hour prior to IHCA

7 As evident in Figure 1C which describes the clinical conditions preceding (up to 60 minutes)
8 the cardiac arrest, hypoxia was more common among COVID+ (57%), as compared with
9 COVID- (34%). Regarding arrhythmia, heart failure, hypotension and seizure the percentages
10 were more similar.

11 Survival analysis

12 The Kaplan Meier plots (Figure 2) show that COVID+ cases generally had a lower
13 probability of survival compared to COVID- and UNA cases. The overall 30-day survival
14 (Figure 2A) was 21% among COVID+, compared with 36% in COVID- cases (p=0.00086).
15 The subgroup analysis of women (Figure 2B) showed low survival rates in COVID+ cases
16 (16% 30-day survival). Regarding age, 30 days survival among COVID+ aged <70 years was
17 25% (Figure 2E), as compared with 18% of COVID+ cases aged 70 or older (Figure 2D).
18 Patients with acute MI had a 30 days survival of 8% among COVID+ cases (Figure 2J).

1 Survival curves for the subgroups of individuals with cancer, heart failure and diabetes, did
2 not display any clear patterns (Figure 2F-2H). All p values were >0.1.

3 Cox adjusted survival curves are presented in Supplementary Figure 5; COVID+ cases
4 displayed the lowest probability of survival, whereas there was no material difference
5 between COVID- and UNA cases.

6 **Odds ratios for 30-days survival**

7 When adjusted for age, sex and initial rhythm the odds ratio for 30-day survival, comparing
8 COVID+ vs. COVID-, were 0.50 (0.33-0.76) overall, 0.53 (0.31-0.88) for men, and 0.44
9 (0.20-0.88) for women. In the subgroup of patients with heart failure, myocardial infarction
10 and cancer, we found no statistically significant associations, whereas in the subgroup of
11 COVID+ patients with kidney failure, odds ratio for 30-days survival was 0.43 (0.16-0.99),
12 when compared with COVID- (Figure 3).

13 **Predictors of survival**

14 Regarding predictors for 30-days survival among COVID+ we note that confidence intervals
15 were generally wide. Lack of ECG monitoring and later start of CPR showed point estimates
16 below 1.0, although non-significant. Odds ratio for patients treated in non-monitored wards

1 was 0.26 (95% CI 0.08-0.78) as compared with monitored ward(Figure 4). No coexisting
condition was associated with survival among COVID+ cases.

Regarding COVID- cases the factors that were significantly associated with 30-days survival
were shockable rhythm (OR 4.18 [95% CI 2.69–6.02]), ECG monitoring (2.67 [95% CI 1.82–
3.95]), heart failure (OR 0.58 [95% CI 0.40–0.83]) and diabetes (OR 0.64 [95% CI 0.44–
0.92]) were significantly associated with death(Figure 4).

Discussion

This study elucidates characteristics and outcomes in patients with COVID-19 who develop
IHCA. To the best of our knowledge, this is the largest study on IHCA with individual level
COVID-19 data. We show that most characteristics (e.g., underlying etiology, initial rhythm,
conditions preceding cardiac arrest), as well as survival, differs markedly in COVID+ cases
compared with COVID-, with the former group exhibiting worse characteristics and
outcomes. Importantly, survival in COVID+ cases was half that of COVID- cases. As of
writing this report the pandemic is still surging worldwide with hundreds of thousands of new
cases every day. The results of our study are relevant for any health care system handling
patients infected with COVID-19.

1
2
3
4 1 Regarding location of CA, we note that the most common location for COVID-19 patients
5
6
7 2 was regular wards, which are not monitored. This is unfortunate since our regression analysis
8
9
10 3 showed that type of ward (monitored vs non-monitored) was significantly associated with
11
12
13 4 survival, such that COVID+ cases in non-monitored wards displayed 74% lower probability
14
15
16 5 of survival as compared with COVID+ cases in monitored wards. As compared with COVID-
17
18
19 6 cases, cardiac arrest in the ER was more common in COVID+ cases. The often rapid
20
21
22
23 7 deterioration of cardiopulmonary function in patients with COVID-19 may be one of the
24
25
26 8 explanations for this finding. Fewer COVID+ cases were located in the CCU which is an
27
28
29 9 expected finding due to the fact that cardiac etiology was less common among these patients.
30
31
32
33
34 10 There were high rates of COVID-19 associated cases in April and May and as expected the
35
36
37 11 number of patients started increasing again from September onwards to reach 19% in
38
39
40
41 12 December at the end of our study. At the moment the incidence of severe COVID-19 cases in
42
43
44 13 Sweden is still high.
45
46
47
48 14 In this study we note that the most common cause of cardiac arrest in COVID+ cases, as well
49
50
51 15 as the most frequent clinical condition directly preceding the arrest, is respiratory. The high
52
53
54 16 rate of respiratory etiology was driven by men (Supplementary Figure 6-7). A total of 57% of
55
56
57
58 17 cases displayed hypoxia before cardiac arrest. This may highlight an opportunity for
59
60

1
2
3
4 1 improving outcomes; measures to prevent hypoxia and to correct it immediately may reduce
5
6
7 2 the risk of cardiac arrest in patients with COVID-19. On the other hand, it can be argued that
8
9
10 3 we cannot do that inference because we have not studied patients with and without hypoxia
11
12
13 4 and followed them in terms of risk of developing cardiac arrest (all our cases had already
14
15
16 5 developed cardiac arrest). However, we know that COVID-19 causes ARDS (acute
17
18
19 6 respiratory distress syndrome) and hypoxia, which can induce cardiac arrest.
20
21
22
23
24 7 The fact that COVID+ cases were ventilated (prior to arrival of the rescue team) less
25
26
27 8 frequently than all other patients was expected, despite the fact that they displayed higher
28
29
30 9 rates of hypoxia prior to cardiac arrest, as well as respiratory etiology. This observation is
31
32
33
34
35 10 likely explained by the fact that Swedish guidelines were revised during March 2020 as well
36
37
38
39 11 as the guidelines from the European Resuscitation Council, with the recommendation that
40
41
42 12 mouth-to-mouth ventilation and pocket mask ventilation should be avoided in case with
43
44
45 13 confirmed or suspected COVID-19(10). Whether or not this resulted in worse outcomes for
46
47
48
49 14 COVID- 19 cases remain unsolved.
50
51
52
53 15 However, the fact that 43% of cases with COVID-19 did not have hypoxia prior to cardiac
54
55
56 16 arrest suggests that other factors are important as well. Thromboembolism, myocardial
57
58
59 17 infarction, arrhythmias, etc. may all contribute to the development of a cardiac arrest(11).

1
2
3
4 1 A previous study from Wuhan showed that 87.5% of COVID+ cases with in-hospital cardiac
5
6
7 2 arrest had a respiratory etiology(5). We report much lower rates (24%), which may be due to
8
9
10 3 several factors; e.g. in our study we had a total of 22 possible categories for cause of CA, as
11
12
13 4 compared with two categories in the study from Wuhan. Also, patients in the study from
14
15
16 5 Wuhan had severe COVID-19 and in our study population we do not know the severity of the
17
18
19
20 6 disease.

21
22
23
24 7 The survival rates were poor among COVID+ patients with an overall 30-days survival of
25
26
27 8 21%, compared to 36% among COVID-. The survival rate was, however, not as low as in the
28
29
30 9 study from Wuhan, in which 3% (151 patients studied) survived, or in the study from New
31
32
33
34 10 York with 31 patients with none surviving(5, 12). One reason for the poor survival could be
35
36
37 11 the small number of patients found in a shockable rhythm (17% vs. 25% for COVID+ and
38
39
40 12 COVID-, respectively) since patients with shockable rhythm have a more favorable outcome.
41
42
43
44 13 After adjusting for sex, age and shockable rhythm the 30-day survival was though still
45
46
47 14 significantly worse among patients with an ongoing infection.

48
49
50
51 15 In our previous study we showed that COVID+ women had an odds ratio of 7.63
52
53
54 16 (1.97–50.93) for 30-days mortality, as compared with COVID- women. The wide confidence
55
56
57
58 17 interval in the previous study is mostly explained by lack of statistical power. In this study, in
59
60

1
2
3
4 1 which more patients were included, we demonstrate that COVID+ women had halved chance
5
6
7 2 of survival at 30 days, compared with COVID– women(6). We find it interesting that
8
9
10 3 COVID+ women had acute MI three times as often as men, despite the fact that men
11
12
13 4 exhibited shockable rhythm – and were defibrillated – twice as often as women; this cannot
14
15
16
17 5 be explained by differences in prevalent heart failure, as there were none across men and
18
19
20 6 women.

21
22
23
24 7 **Strengths and limitations.** This study includes all IHCA in Sweden which were reported to
25
26
27 8 SRCR. The sample recorded in the SRCR is unbiased since all hospitals participate in the
28
29
30 9 registry and all hospitals report data on COVID-19 status. However, we do not know the
31
32
33
34 10 severity of the COVID-19 infection, and we do not know if COVID-19 was the main reason
35
36
37
38 11 for admission to hospital. With regards to the classification of COVID-19 status, we have
39
40
41 12 recently performed a misclassification analysis which demonstrated that odds ratios were not
42
43
44 13 materially affected by misclassification bias. Our study only includes IHCA receiving CPR.
45
46
47 14 This leaves out all other patients with IHCA, e.g with a Do Not Attempt Resuscitation order.
48
49
50
51 15 It is important to stress the fact that our regression model that included only COVID-19 cases
52
53
54 16 must be interpreted with caution due to the large number of predictors in the model, which
55
56
57
58 17 had relatively few patients (resulting in wide confidence intervals). Further studies are
59
60

1 warranted, using a larger study population, and a longer follow up especially regarding
2 subgroup analyses, neurological outcomes and the quality of life for the patients. Information
3 about the severity of COVID-19 and the reason for admission to the hospital would add
4 valuable insights as well.

5 **Conclusion**

6 During pandemic peaks, up to one fourth of all IHCA's are complicated by COVID-19, and
7 these patients have halved chance of survival, with women displaying the worst outcomes.

8 While our previous study did not identify any COVID+ cases that were discharged alive, we
9 now show that 19% of COVID+ cases are discharged alive, which is half the rate among
10 COVID- cases.

11 **Funding**

12 This work was supported by the Swedish Research Council [2019-02019] and the Swedish
13 Heart and Lung Foundation [20200261].

14 **Conflict of interest:** none declared.

15 **Author Statement:** Astrid Holm and Araz Rawshani designed the study. Astrid Holm has been
16 the main author and been in charge of the analysis and interpretation of data. Araz Rawshani

1
2
3
4 1 has been supervising. Matilda Jerkeman, Pedram Sultanian, Peter Lundgren, Annica Ravn-
5
6
7 2 Fischer, Johan Israelsson, Jasna Giesecke and Johan Herlitzwere were all co-writers, revised
8
9
10 3 the article critically for important intellectual content and approved the version of the article
11
12
13
14 4 to be published.
15
16
17
18

19 5 **References**

- 20
21 6 1. Johns Hopkins University and Medicine COVID-19 map [internet] Johns Hopkins
22 7 Coronavirus Resource Centre 2020. [updated 13/5/2021. Available from:
23 8 <https://coronavirus.jhu.edu/map.html>.
24 9 2. Dödsorsaker första halvåret 2020. Socialstyrelsen. Hälsa- och sjukvård.; 2020
25 10 17/11/2020.
26 11 3. Andersson J. Samhällsspridning av coronaviruset i Sverige. Läkartidningen.
27 12 16/03/2020.
28 13 4. Hayek SS, Brenner SK, Azam TU, Shadid HR, Anderson E, Berlin H, et al. In-hospital
29 14 cardiac arrest in critically ill patients with covid-19: multicenter cohort study. *Bmj*. 2020;371:m3513.
30 15 5. Shao F, Xu S, Ma X, Xu Z, Lyu J, Ng M, et al. In-hospital cardiac arrest outcomes among
31 16 patients with COVID-19 pneumonia in Wuhan, China. *Resuscitation*. 2020;151:18-23.
32 17 6. Sultanian P, Lundgren P, Strömsöe A, Aune S, Bergström G, Hagberg E, et al. Cardiac
33 18 arrest in COVID-19: characteristics and outcomes of in- and out-of-hospital cardiac arrest. A report
34 19 from the Swedish Registry for Cardiopulmonary Resuscitation. *European Heart Journal*. 2021.
35 20 7. Hessulf F, Herlitz J, Rawshani A, Aune S, Israelsson J, Södersved-Källestedt ML, et al.
36 21 Adherence to guidelines is associated with improved survival following in-hospital cardiac arrest.
37 22 *Resuscitation*. 2020;155:13-21.
38 23 8. Stef van Buuren, Groothuis-Oudshoorn K. mice: Multivariate Imputation by Chained
39 24 Equations in R. *Journal of Statistical Software*. 2011;Vol 45.
40 25 9. 3.5 Classification and regression trees [Available from:
41 26 <https://stefvanbuuren.name/fimd/sec-cart.html>.
42 27 10. Nolan JP, Monsieurs KG, Bossaert L, Böttiger BW, Greif R, Lott C, et al. European
43 28 Resuscitation Council COVID-19 guidelines executive summary. *Resuscitation*. 2020;153:45-55.
44 29 11. Gupta A, Madhavan MV, Sehgal K, Nair N, Mahajan S, Sehrawat TS, et al.
45 30 Extrapulmonary manifestations of COVID-19. *Nat Med*. 2020;26(7):1017-32.
46 31 12. Sheth V, Chishti I, Rothman A, Redlener M, Liang J, Pan D, et al. Outcomes of in-
47 32 hospital cardiac arrest in patients with COVID-19 in New York City. *Resuscitation*. 2020;155:3-5.
48
49
50
51
52
53 33
54
55
56
57 34
58
59
60

Table 1 Characteristics of 1613 patients with IHCA during the COVID-19 pandemic.

Variables	No infection COVID –	Ongoing infection COVID +	Unknown/N A UNA	SMD
n	1062	182	369	
Demographics:				
Age - mean (SD)	71.00 (13.32)	70.93 (12.43)	70.22 (13.60)	0.039
Woman - n (%)	388 (36.6)	68 (37.6)	151 (41.0)	0.061
Location of cardiac arrest - n (%)				0.527
Coronary care unit - n (%)	155 (14.6)	14 (7.7)	50 (13.6)	
Intensive care unit - n (%)	77 (7.3)	25 (13.7)	19 (5.1)	
Operational room - n (%)	22 (2.1)	0 (0.0)	12 (3.3)	
Emergency room - n (%)	139 (13.1)	29 (15.9)	65 (17.6)	
Outpatient lab, radiology - n (%)	49 (4.6)	7 (3.8)	28 (7.6)	
Cathlab - n (%)	98 (9.2)	8 (4.4)	60 (16.3)	
Intermediate care unit - n (%)	25 (2.4)	15 (8.2)	10 (2.7)	
Regular ward - n (%)	468 (44.1)	82 (45.1)	116 (31.4)	
Other - n (%)	29 (2.7)	2 (1.1)	9 (2.4)	
Critical times - median (IQR):				
Time to alert – median (IQR)	1.00 [1.00, 1.00]	1.00 [1.00, 1.00]	1.00 [1.00,	0.078
Time to CPR - median (IQR)	0.00 [0.00, 1.00]	0.00 [0.00, 0.00]	0.00 [0.00,	0.109
Time to defibrillation - median (IQR)	2.00 [1.00, 5.00]	2.00 [1.00, 4.75]	1.00 [1.00,	0.141
Comorbidities - n (%):				
MI, ongoing - n (%)	178 (23.6)	12 (12.0)	37 (29.4)	0.292
MI, previous - n (%)	163 (20.8)	13 (11.7)	26 (18.4)	0.165
Stroke, ongoing - n (%)	30 (3.8)	4 (3.7)	4 (3.0)	0.030
Stroke, previous - n (%)	82 (10.3)	7 (6.1)	15 (10.5)	0.105
Cancer, any - n (%)	165 (20.9)	20 (17.7)	28 (20.6)	0.054
Diabetes - n (%)	224 (27.9)	36 (31.0)	38 (27.0)	0.060
Heart failure - n (%)	229 (29.7)	36 (33.0)	36 (27.9)	0.074
Ejection fraction (%) - mean (SD)	46.14 (13.74)	46.44 (11.86)	44.94 (14.82)	0.073
EF <50% - n (%)	167 (46.0)	26 (48.1)	22 (46.8)	0.029
Kidney function category - n (%)				0.121
eGFR <30 - n (%)	165 (21.6)	22 (20.0)	26 (20.0)	
eGFR 30–59- n (%)	216 (28.3)	32 (29.1)	44 (33.8)	
eGFR 60–89 - n (%)	198 (25.9)	25 (22.7)	30 (23.1)	
eGFR ≥90 - n (%)	185 (24.2)	31 (28.2)	30 (23.1)	
No kidney failure (eGFR ≥60) - n (%)	383 (50.1)	56 (50.9)	60 (46.2)	0.063
eGFR (ml/min/m ²) - mean (SD)	66.89 (49.43)	71.26 (58.96)	63.78 (40.31)	0.099
Cause of arrest: - n (%)				0.629
Hemorrhage - n (%)	34 (4.9)	2 (2.0)	10 (8.1)	
Myocardial infarction/ischemia- n (%)	181 (26.2)	15 (14.9)	41 (33.3)	
Other - n (%)	213 (30.8)	30 (29.7)	41 (33.3)	
Primary arrhythmia - n (%)	101 (14.6)	8 (7.9)	12 (9.8)	
Respiratory insufficiency - n (%)	73 (10.5)	24 (23.8)	7 (5.7)	
Sepsis/infection - n (%)	45 (6.5)	19 (18.8)	4 (3.3)	

Stroke/thromboembolism - n (%)	45 (6.5)	3 (3.0)	8 (6.5)	
Early interventions - n (%):				
Witnessed arrest - n (%)	857 (80.9)	140 (77.8)	306 (85.0)	0.124
ECG monitoring - n (%)	635 (60.5)	89 (50.0)	221 (62.1)	0.163
CPR before AGA - n (%)	845 (91.0)	146 (93.6)	268 (88.2)	0.127
Defibrillated before AGA - n (%)	159 (17.9)	18 (11.9)	53 (19.0)	0.131
Ventilated before AGA - n (%)	503 (63.2)	74 (54.8)	175 (69.2)	0.199
Shockable rhythm - n (%)	247 (24.9)	29 (17.3)	90 (27.0)	0.158
Defibrillated, any - n (%)	323 (31.5)	40 (22.7)	111 (32.8)	0.151
Intubated - n (%)	473 (47.0)	100 (57.8)	177 (53.8)	0.145
Adrenaline given - n (%)	668 (65.6)	125 (72.7)	223 (66.4)	0.102
Antiarrhythmics - n (%)	139 (14.1)	17 (10.1)	48 (15.4)	0.107
Mechanical compressions - n (%)	109 (10.8)	18 (10.4)	66 (20.0)	0.180
Active temperature control - n (%)	54 (11.3)	5 (10.4)	3 (4.4)	0.173
Status at rescue team arrival - n (%):				
Consciousness - n (%)	214 (23.1)	18 (11.7)	57 (19.3)	0.204
Breathing - n (%)	288 (31.2)	30 (19.5)	84 (28.7)	0.181
Pulse - n (%)	309 (33.8)	36 (23.4)	89 (30.4)	0.154
Follow-Up data - n (%):				
Angiography - n (%)	115 (24.2)	8 (16.7)	15 (20.8)	0.124
PCI - n (%)	87 (18.2)	4 (8.3)	16 (21.9)	0.258
Pacemaker implanted - n (%)	80 (16.7)	2 (4.2)	4 (5.6)	0.281
ICD implanted - n (%)	36 (7.5)	1 (2.1)	2 (2.8)	0.172
ROSC - n (%)	520 (49.0)	64 (35.2)	142 (38.5)	0.188
Death at 30 days - n (%)	666 (62.7)	141 (77.5)	237 (64.2)	0.218
Death overall - n (%)	703 (66.2)	141 (77.5)	241 (65.3)	0.181
Discharged alive - n (%)	283 (35.6)	22 (19.0)	39 (26.5)	0.253

SD = standard deviation; IQR = interquartile range; SMD = standardized mean difference (difference between the means for the two groups divided by their mutual standard deviation. Values below 0.1 (10%) are considered inconsequential (i.e., no significant difference between the groups)). CPR = Cardiopulmonary resuscitation, PCI = Percutaneous Coronary Intervention, ICD = implantable cardioverter-defibrillator. ROSC = return of spontaneous circulation. AGA= alarm group arrival

1

2

1 **Figure Titles and Legends**

2 **Figure 1: Characteristics of IHCA according to COVID-19 status**

3 A: Monthly proportion of COVID-19 status among patients with IHCA, stratified on COVID-
4 19 status. In March only cases after 15/03/2020 were included.

5 B: Etiology of IHCA, stratified on COVID-19 status. The y-axis shows percentages for each
6 etiology in each group.

7 C: Clinical conditions 1 hour prior to IHCA, stratified on COVID-19 status. Only patients
8 with data regarding the specific condition was included.

9 **Figure 2: Kaplan Meier survival curves**

10 Kaplan Meier survival curves, separately for (A)Overall, (B)Women, (C)Men, (D)Age ≥ 70
11 year, (E)Age < 70 year, (F)Cancer, (G)Heart failure, (H)Diabetes, (I)Kidney failure and
12 (J)Myocardial infarction. $p = \log$ -rank p -value. The numbers under the graphs are showing the
13 survival in percentages. Regarding myocardial infarction acute MI is presented.

14 **Figure 3: Odds Ratio for 30-day survival**

15 Forest plot with the adjusted odds ratio for 30-day survival among patients with ongoing
16 infection vs. no infection and unknown/NA vs. no infection. Stratified on overall, men,

1
2
3
4 1 women, age < 70 years, age ≥ 70 years, heart failure, kidney failure, diabetes, myocardial
5
6
7 2 infarction and cancer. Myocardial infarction was defined as acute or previous MI.

8
9
10
11 3 **Figure 4: Odds Ratio for 30-day survival**

12
13
14 4 Forest plot with odds ratio for 30-day survival, stratified on the groups, no infection, ongoing
15
16
17
18 5 infection and overall, all in different colors. The 95% Confidence interval is shown between
19
20
21 6 the bars. X-axis has a logarithmic scale. ECG=electrocardiogram, CA=cardiac arrest,
22
23
24 7 MI=myocardial infarction. CI=confidence interval.

25
26
27
28 8
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Figure 1: Characteristics of IHCA according to COVID-19 status




Figure 1A: Monthly proportion of COVID-19 status among patients with IHCA, stratified on COVID-19 status. In March only cases after 15/03/2020 were included.




Figure 1B: Etiology of IHCA, stratified on COVID-19 status. The y-axis shows percentages for each etiology in each group.




Figure 1C: Clinical conditions 1 hour prior to IHCA, stratified on COVID-19 status. Only patients with data regarding the specific condition was included.

Figure 2: Kaplan Meier survival curves




Figure 2: Kaplan Meier survival curves, separately for (A) Overall, (B) Women, (C) Men, (D) Age ≥70 year, (E) Age <70 year, (F) Cancer, (G) Heart failure, (H) Diabetes, (I) Kidney failure and (J) Myocardial infarction. p= log-rank p-value. The numbers under the graphs are showing the survival in percentages. Regarding myocardial infarction acute MI is

Figure 3: Odds Ratio for 30-day survival




Figure 3: Forest plot with the adjusted odds ratio for 30-day survival among patients with ongoing infection vs. no infection and unknown/NA vs. no infection. Stratified on overall, men, women, age < 70 years, age ≥ 70 years, heart failure, kidney failure, diabetes, myocardial infarction and cancer. Myocardial infarction was defined as acute or previous MI.

Figure 4: Odds Ratio for 30-day survival



Figure 4: Forest plot with odds ratio for 30-day survival, stratified on the groups, no infection, ongoing infection and overall, all in different colors. The 95% Confidence interval is shown between the bars. X-axis has a logarithmic scale. ECG= electrocardiogram, CA= cardiac arrest, MI= myocardial infarction. CI= confidence interval.

1
2
3
4 **Supplementary figures and tables**
5

6
7 **Characteristics and Outcomes in Patients**
8 **with COVID-19 and In-Hospital Cardiac**
9 **Arrest**
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Supplementary Table 1: Characteristics of COVID+ patients with IHCA in relation to sex.


Supplementary Table 1: Characteristics of 181 COVID+ patients with IHCA during the COVID-19 pandemic in relation to sex. One COVID+ patient had missing data on sex.

variables	Men	Women	SMD
n	113	68	
Demographics:			
Age - mean (SD)	71.39 (10.75)	70.35 (14.87)	0.080
Location of cardiac arrest - n (%):			0.249
Coronary care unit	7 (6.2)	7 (10.3)	
Intensive care unit	15 (13.3)	10 (14.7)	
Operational room	0 (0.0)	0 (0.0)	
Emergency room	17 (15.0)	11 (16.2)	
Outpatient lab, radiology	4 (3.5)	3 (4.4)	
Cathlab	6 (5.3)	2 (2.9)	
Intermediate care unit	11 (9.7)	4 (5.9)	
Regular ward	52 (46.0)	30 (44.1)	
Other	1 (0.9)	1 (1.5)	
Critical times - median (IQR):			
Time to alert – median (IQR)	1.00 [1.00, 1.00]	1.00 [1.00, 1.00]	0.256
Time to CPR - median (IQR)	0.00 [0.00, 0.00]	0.00 [0.00, 1.00]	0.031
Time to defibrillation - median	2.00 [1.00, 5.00]	2.00 [1.00, 2.00]	0.009
Comorbidities - n (%):			
MI, ongoing - n (%)	5 (7.6)	7 (21.2)	0.396
MI, previous - n (%)	11 (16.4)	2 (4.7)	0.391
Stroke, ongoing - n (%)	4 (5.8)	0 (0.0)	0.351
Stroke, previous - n (%)	5 (7.0)	2 (4.7)	0.102
Cancer, any - n (%)	13 (18.8)	6 (14.0)	0.132
Diabetes - n (%)	24 (33.3)	12 (27.9)	0.118
Heart failure - n (%)	23 (33.8)	13 (32.5)	0.028
Ejection fraction (%) - mean (SD)	44.84 (12.22)	49.31 (10.56)	0.392
EF <50% - n (%)	19 (51.4)	7 (43.8)	0.153
Kidney function category - n (%):			0.357
eGFR <30	16 (22.9)	6 (15.0)	
eGFR 30–59	17 (24.3)	15 (37.5)	
eGFR 60–89	18 (25.7)	7 (17.5)	
eGFR ≥90	19 (27.1)	12 (30.0)	
No kidney failure (eGFR ≥60)	37 (52.9)	19 (47.5)	0.107
eGFR (ml/min/m ²) - mean (SD)	72.72 (65.75)	68.70 (45.34)	0.071
Cause of arrest - n (%):			0.920
Hemorrhage	1 (1.5)	1 (2.9)	
Myocardial infarction/ischemia	7 (10.6)	8 (23.5)	
Other	18 (27.3)	12 (35.3)	
Primary arrhythmia	3 (4.5)	5 (14.7)	
Respiratory insufficiency	17 (25.8)	7 (20.6)	

Sepsis / infection	18 (27.3)	1 (2.9)	
Stroke / thromboembolism	2 (3.0)	0 (0.0)	
Early interventions - n (%):			
Witnessed arrest - n (%)	86 (76.8)	53 (79.1)	0.056
ECG monitoring - n (%)	56 (50.5)	33 (50.0)	0.009
CPR before AGA - n (%)	90 (92.8)	55 (94.8)	0.085
Defibrillated before AGA - n (%)	13 (13.8)	5 (8.9)	0.155
Ventilated before AGA- n (%)	49 (56.3)	25 (53.2)	0.063
Shockable rhythm - n (%)	22 (20.8)	7 (11.5)	0.254
Defibrillated, any - n (%)	29 (26.4)	11 (16.9)	0.231
Intubated - n (%)	61 (57.0)	38 (58.5)	0.029
Adrenaline given - n (%)	76 (70.4)	48 (76.2)	0.132
Antiarrhythmics - n (%)	11 (10.4)	6 (9.7)	0.023
Mechanical compressions - n (%)	12 (10.9)	5 (8.1)	0.097
Active temperature control - n (%)	2 (6.1)	3 (20.0)	0.423
Status at rescue team arrival - n			
Consciousness - n (%)	11 (11.3)	6 (10.7)	0.020
Breathing - n (%)	18 (18.6)	11 (19.6)	0.028
Pulse - n (%)	22 (22.7)	13 (23.2)	0.013
Follow-Up data - n (%):			
Angiography - n (%)	4 (12.1)	4 (26.7)	0.374
PCI - n (%)	2 (6.1)	2 (13.3)	0.248
Pacemaker implanted - n (%)	0 (0.0)	2 (13.3)	0.555
ICD implanted - n (%)	0 (0.0)	1 (6.7)	0.378
ROSC - n (%)	40 (35.4)	24 (35.3)	0.002
Death at 30 days - n (%)	85 (75.2)	56 (82.4)	0.175
Death overall - n (%)	85 (75.2)	56 (82.4)	0.175
Discharged alive - n (%)	16 (22.2)	6 (14.0)	0.216


SD = standard deviation; IQR = interquartile range; SMD = standardized mean difference (difference between the means for the two groups divided by their mutual standard deviation. Values below 0.1 (10%) are considered inconsequential (i.e., no significant difference between the groups)). CPR = cardiopulmonary resuscitation, PCI = percutaneous coronary intervention, ICD = implantable cardioverter-defibrillator. ROSC = return of spontaneous circulation. AGA= alarm group arrival.

Supplementary Figure 1: Missing data before and after imputation with MICE




Supplementary Figure 1: Missing data before and after imputation with MICE. A graphical view of the entire dataset is printed. Each column (variable) is depicted at the top and column color depicts type of variable. Each patient represents a row and white gaps indicate a missing data entry.

Supplementary Figure 2: Flow chart




Supplementary Figure 2: Flow chart of the study population. Patients who were less than 18 year of age, and cases occurring in the pre-pandemic period were excluded.

Supplementary Figure 3: Information on COVID-19 status during the study period.




Supplementary Figure 3: Information on COVID-19 status during the study period. No equals missing data, i.e. no information on COVID-19 status available. Yes equals, COVID +, COVID – or Unknown. In March only cases after 15/03/2020 were included.

Supplementary Figure 4: Distribution of age




Supplementary Figure 4: Distribution of age in relation to COVID-19 status.

Supplementary Figure 5: Etiology of IHCA, according to sex




Supplementary Figure 5A: Etiology of IHCA, men only.




Supplementary Figure 5B: Etiology of IHCA, women only.

Supplementary Figure 6: Conditions preceding IHCA, according to sex




Supplementary Figure 6A: Conditions preceding IHCA, men only.



Supplementary Figure 6B: Conditions preceding IHCA, women only.

Supplementary Figure 7: Cox adjusted survival curve for the overall population



Supplementary Figure 7: Cox adjusted survival curve for the overall population, stratified on COVID-19 status.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

STROBE Statement—checklist of items that should be included in reports of observational studies

	Item No	Recommendation	Page No
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	1
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	2-3
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	2
Objectives	3	State specific objectives, including any prespecified hypotheses	2
Methods			
Study design	4	Present key elements of study design early in the paper	2
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	2
Participants	6	(a) <i>Cohort study</i> —Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up <i>Case-control study</i> —Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls <i>Cross-sectional study</i> —Give the eligibility criteria, and the sources and methods of selection of participants	2
		(b) <i>Cohort study</i> —For matched studies, give matching criteria and number of exposed and unexposed <i>Case-control study</i> —For matched studies, give matching criteria and the number of controls per case	2
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	5-6
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	5
Bias	9	Describe any efforts to address potential sources of bias	3-4
Study size	10	Explain how the study size was arrived at	5
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	5-6
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	6-7
		(b) Describe any methods used to examine subgroups and interactions	6-7
		(c) Explain how missing data were addressed	6-7
		(d) <i>Cohort study</i> —If applicable, explain how loss to follow-up was addressed <i>Case-control study</i> —If applicable, explain how matching of cases and controls was addressed <i>Cross-sectional study</i> —If applicable, describe analytical methods taking account of sampling strategy	6-7
		(e) Describe any sensitivity analyses	6-7

Continued on next page

Results			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	7
		(b) Give reasons for non-participation at each stage	7
		(c) Consider use of a flow diagram	Supplementary material
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	7-8
		(b) Indicate number of participants with missing data for each variable of interest	7-8
		(c) <i>Cohort study</i> —Summarise follow-up time (eg, average and total amount)	7
Outcome data	15*	<i>Cohort study</i> —Report numbers of outcome events or summary measures over time	8-9
		<i>Case-control study</i> —Report numbers in each exposure category, or summary measures of exposure	
		<i>Cross-sectional study</i> —Report numbers of outcome events or summary measures	
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	7-10
		(b) Report category boundaries when continuous variables were categorized	
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	Supplementary material
Discussion			
Key results	18	Summarise key results with reference to study objectives	11
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	13-14
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	11-14
Generalisability	21	Discuss the generalisability (external validity) of the study results	14
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	14

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.

For peer review only

BMJ Open

A Cohort Study of the Characteristics and Outcomes in Patients with COVID-19 and In-Hospital Cardiac Arrest

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2021-054943.R1
Article Type:	Original research
Date Submitted by the Author:	30-Sep-2021
Complete List of Authors:	<p>Holm, Astrid; University of Gothenburg, Department of Molecular and Clinical Medicine Jerkeman, Matilda; University of Gothenburg, Department of Molecular and Clinical Medicine Sultanian, Pedram; University of Gothenburg, Department of Molecular and Clinical Medicine Lundgren, Peter; University of Gothenburg, Department of Molecular and Clinical Medicine; Kalmar County Hospital, Department of Internal Medicine Ravn-Fischer, Annica; University of Gothenburg, Department of Molecular and Clinical Medicine Israelsson, Johan; Kalmar County Hospital, Department of Internal Medicine; Linnaeus University, Faculty of Health and Life Sciences Giesecke, Jasna; Danderyd University Hospital Herlitz, Johan; University of Borås, Centre for Prehospital Research Rawshani, Araz; University of Gothenburg, Department of Molecular and Clinical Medicine</p>
Primary Subject Heading:	Cardiovascular medicine
Secondary Subject Heading:	Cardiovascular medicine, Infectious diseases
Keywords:	COVID-19, CARDIOLOGY, Adult cardiology < CARDIOLOGY, Coronary heart disease < CARDIOLOGY

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

A Cohort Study of the Characteristics and Outcomes in Patients with COVID-19 and In-Hospital Cardiac Arrest

Astrid Holm, MD¹, Matilda Jerkeman, MD¹, Pedram Sultanian, MD¹, Peter Lundgren, MD, PhD^{1,3,7}, Annica Ravn-Fischer, MD, PhD, Docent¹, Johan Israelsson, PhD^{3,4}, Jasna Giesecke, RN⁵, Johan Herlitz, MD, PhD^{2,6}, Araz Rawshani, MD, PhD^{1,2}

Affiliations:

¹Department of Molecular and Clinical Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Sweden

²The Swedish Registry for Cardiopulmonary Resuscitation, Centre of Registries, Västra Götaland County, Sweden

³Department of Internal Medicine, Division of Cardiology, Kalmar County Hospital, Region Kalmar County, Sweden

⁴Faculty of Health and Life Sciences, Linnaeus University, Kalmar, Sweden

⁵RN, Lead CPR coordinator, Clinicum- Centre for clinical skills, interprofessional education and advanced medical simulation, Danderyd University Hospital, Stockholm, Sweden

⁶Prehospiten – Centre for Prehospital Research, University of Borås, Borås, Sweden

⁷Region Västra Götaland, Sahlgrenska University Hospital, Department of Cardiology, Gothenburg, Sweden

Contact information:

Astrid Holm

Email: astrid.holm@gu.se

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Phone: +358 400707722

Manuscript word count: 3442

Key Points

Question: What are the Characteristics, causes and outcomes in patients with COVID-19 who suffer an in-hospital cardiac arrest (IHCA)?

Findings: In the registry-based observational study we found that during pandemic peaks, up to one fourth of all IHCAs are complicated by COVID-19, and these patients have halved chance of survival.

Meaning: The survival rate of patients with COVID-19 associated IHCA is low with women displaying the worst outcomes.

Abstract

Objective: We studied characteristics, survival, causes of cardiac arrest, conditions preceding cardiac arrest, predictors of survival, and trends in the prevalence of COVID-19 among IHCA cases. Data on characteristics and outcomes in patients with COVID-19 who suffer an in-hospital cardiac arrest (IHCA) is scarce.

Design and setting: Registry-based observational study.

Participants: We studied all cases of IHCA receiving CPR (≥ 18 years of age) in the Swedish Registry for Cardiopulmonary Resuscitation from 15/03/2020 to 31/12/2020. A total of 1613

1
2
3 patients were included and divided into the following groups: ongoing infection (**COVID+**;
4
5
6 n=182), no infection (**COVID-**; n=1062) and unknown/not assessed (**UNA**; n=369).
7
8
9

10 **Main outcomes and measures:** We studied monthly trends in proportions of COVID-19
11
12 associated IHCAs, causes of IHCA in relation to COVID-19 status, clinical conditions
13
14 preceding the cardiac arrest and predictors of survival.
15
16
17
18
19

20
21 **Results:** The rate of COVID+ patients suffering an IHCA increased to 23% during the first
22
23 pandemic wave (April), then abated to 3% in July, and then increased to 19% during the
24
25 second wave (December). Among COVID+ cases, 43% had respiratory insufficiency or
26
27 infection as the underlying cause of the cardiac arrest, compared to 18% among COVID-
28
29 cases. The most common clinical sign preceding cardiac arrest was hypoxia (57%) among
30
31 COVID+ cases. Odds ratio for 30-day survival for COVID+ cases was 0.50 (95% CI 0.33-
32
33 0.76) compared with COVID- cases.
34
35
36
37
38
39
40
41
42
43
44

45 **Conclusion:** During pandemic peaks, up to one fourth of all IHCAs are complicated by
46
47 COVID-19, and these patients have halved chance of survival, with women displaying the
48
49 worst outcomes.
50
51
52
53
54
55
56
57
58
59
60

Article Summary

Strengths and limitations of this study

- A major strength of our study is that it includes all IHCA in Sweden which were reported to the Swedish Registry for Cardiopulmonary Resuscitation.
- The sample recorded in the Swedish Registry for Cardiopulmonary Resuscitation is unbiased since all hospitals participate in the registry and all hospitals report data on COVID-19 status
- A limitation is that we do not know the severity of the COVID-19 infection, and we do not know if COVID-19 was the main reason for admission to hospital.
- Our study only includes IHCA receiving CPR which leaves out all other patients with IHCA, e.g with a Do Not Attempt Resuscitation order.
- It is important to stress the fact that our regression model that included only COVID-19 cases must be interpreted with caution due to the large number of predictors in the model, which had relatively few patients.

Introduction

The COVID-19 pandemic has, as of May 1st 2021 infected over 159,000,000 persons and lead to the demise of over 3,321,000 individuals(1).The Swedish Public Health Authority declared on March 16th 2020 that community spread of COVID-19 had commenced, and COVID-19 is now the third leading cause of death in Sweden(2, 3).

Multiple studies have showed that in-hospital cardiac arrest (IHCA) among patients with COVID-19 is associated with poor survival(4-7). In a study from the U.S. with 260 patients hypoxia was the main cause to Cardiac arrest among over 40% of the patients with COVID-19 and IHCA (6).We studied IHCA in the Swedish Registry for Cardiopulmonary Resuscitation (SRCR) and showed a 2.3-fold increase in 30-day mortality among cases with COVID-19 compared to pre-pandemic cases and this was mainly driven by a 9-fold increase in mortality among women with COVID-19. During the study period no case of IHCA with COVID-19 was discharged alive from the hospital(8).

The current study expands our previous investigation, including more patients, longer follow-up and emphasizes the causes of cardiac arrest in COVID-19, predictors of survival, coexisting conditions, and trends in the prevalence of COVID-19 among IHCA cases.

Methods

Data sources

The study is a registry-based observational study with data obtained from the SRCR during the time period 15/03/2020 to 31/12/2020.

The SRCR is a national quality registry and has included IHCA cases since 2005. The data is collected by trained nurses who report patient data using a web-based protocol. The registry has previously been described in detail(9). Vital status was obtained from the Swedish Population Registry and the last day of follow up was 31/12/2020.

Study population

The study population included all patients ≥ 18 years of age suffering from IHCA and receiving CPR throughout Sweden during the period 15/03/2020 to 31/12/2020. We used 15th of March as the start date of the pandemic as the Swedish Public Health Authority declared on March 16th 2020 that COVID-19 was community spread in Sweden(3). On 1st of April the SRCR started collecting data about COVID-19 status, and retrospectively identified 60 patients with COVID-19 who suffered IHCA during March (they were included in the study). Patients were divided into the following three groups: ongoing infection (COVID+; n=182), no infection (COVID-; n=1062) and unknown/not assessed (UNA; n=369). COVID+ was

1
2
3 defined as patients registered with an ongoing COVID-19 infection, suspected ongoing
4
5
6
7 infection or patients with a recent infection(n=29).
8
9

10 11 **Variable definitions** 12

13
14 In SRCR a patient with cardiac arrest was defined as an unconscious patient with no or
15
16 abnormal breathing, in whom resuscitation or defibrillation was attempted. IHCA was defined
17
18 as cardiac arrest in patients admitted to the hospital.
19
20
21
22

23
24 With regards to previous coexisting conditions heart failure was defined as any heart failure
25
26 described before cardiac arrest. Kidney failure was defined as estimated glomerular filtration
27
28 rate (eGFR) below 60 ml/min/1.73 m², calculated using the highest creatinine before cardiac
29
30 arrest with Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula based
31
32 on sex, age and creatinine. The SRCR records data on the highest creatinine levels analyzed
33
34 up to six months prior to CA. Diabetes was defined as any diabetes diagnosis, regardless of
35
36 type. Cancer was defined as any previously known cancer. Acute myocardial infarction (MI)
37
38 was defined as an MI within 72 hours of CA. **Previous** myocardial infarction was defined as
39
40 MI occurring earlier than 72 hours preceding the CA.
41
42
43
44
45
46
47
48
49
50
51

52
53
54 Regarding clinical conditions one hour prior to CA, arrhythmia was defined as any
55
56
57 arrhythmia, hypoxia was defined as an oxygen saturation below 90%, hypotension was
58
59
60

1
2
3 defined as systolic blood pressure below 90 mmHg, seizure was defined as any seizure with
4
5
6
7 loss of consciousness, and heart failure was defined as any heart failure with pulmonary
8
9
10 edema or severe shortness of breath with rales.

11
12
13 A monitored ward was defined as a coronary care unit(CCU), an intensive care unit(ICU), an
14
15
16 operational room(OR), an emergency room(ER), an intermediate care unit(IMCU) or a
17
18
19 catheterization laboratory(Cath lab). A non-monitored ward was defined as a regular ward
20
21
22
23 (RW). All other wards were defined as other ward, e.g. outpatient lab, radiology department,
24
25
26
27 etc.

31 **Statistical analyses**

32
33 Patient characteristics are reported in means and medians, along with standard deviations and
34
35
36 interquartile ranges, respectively. The Kaplan-Meier estimator was used for defining survival
37
38
39
40 distributions; the log rank test was used to test for differences in survival. Trends in rates of
41
42
43
44 COVID-19 were assessed on a monthly basis during the entire study basis.

45
46
47 Logistic regression was used to calculate odds ratios for 30-days survival. These models
48
49
50
51 assessed the association between COVID-19 status and 30-days survival, while adjusting for
52
53
54 age, sex and initial rhythm (shockable or non-shockable). Subgroup analyzes were done for
55
56
57
58
59
60

1
2
3 men, women, age ≥ 70 years, age < 70 years, heart failure, kidney failure, diabetes, myocardial
4
5
6 infarction and cancer.
7
8
9

10 In order to obtain estimates of overall survival, we used Cox proportional hazards model with
11
12 hours since CA as the time scale. The proportional hazards assumption was fulfilled for all
13
14
15
16
17 variables.
18
19
20

21 We used the MICE (Multiple Imputation By Chained Equations) algorithm to impute missing
22
23 values(10, 11) (Supplementary Figure 1). The imputed data set was used to calculate odds
24
25
26
27 ratios for 30-days survival in the overall group, as well as in COVID+ and COVID- cases.
28
29
30

31 These models included age, sex, initial rhythm, time to start of cardiopulmonary resuscitation
32
33 (CPR), time of CA, previous MI, location (other ward vs monitored, and non-monitored ward
34
35 vs monitored), heart failure, EKG monitoring, diabetes and acute MI.
36
37
38
39
40

41 Analyses were done in R (v. 4.0.3, R Foundation for Statistical Computing) using RStudio.
42
43
44
45

46 **Patient and Public Involvement statement:**

47

48 No patients were involved.
49
50
51
52
53

54 **Results**

55

56 A total of 2,227 patients were enrolled in the SRCR between 01/01/2020 and 31/12/2020.
57
58
59
60

After excluding patients < 18 years ($n=68$) and pre-pandemic cases ($n=546$), 1,613 cases

1
2
3 remained from 15/03/2020 to 31/12/2020 and constituted the final study population
4
5
6
7 (Supplementary Figure 2). There was a high rate of information on COVID-19 status during
8
9
10 the study period among patients registered in the registry (Supplementary Figure 3).
11
12
13

14 **Baseline characteristics**

15
16 The overall mean age was 70.8 years, and the proportion of women was 37.6%. At the end of
17
18
19 follow-up, 341 (32.7%) patients were alive. The mean age was similar in the three groups:
20
21
22
23 70.9 years among COVID+, 71.0 years among COVID– cases, and 70.2 years in cases with
24
25
26 UNA (Supplementary Figure 4). The proportion of women was also similar; 37.6% in
27
28
29 COVID+, 36.6% in COVID– and 41.0% in UNA cases.
30
31
32

33
34 A regular ward (RW) was the most common place of cardiac arrest in all 3 groups with rates
35
36
37 of 45.1% among COVID+, 44.1% among COVID– and 31.4% among UNA (Table 1). The
38
39
40 emergency room (ER) was the second most common location for COVID+ cases (15.9%).
41
42
43
44 The ER was the location of cardiac arrest in 17.6% of UNA cases and 13.1% for COVID–
45
46
47 cases.
48
49

50
51 Regarding comorbidities, acute myocardial infarction was observed in 12.0% of COVID+ and
52
53
54 23.6% of COVID– cases. Previous myocardial infarction was observed in 11.7% of COVID+,
55
56
57
58
59
60

1
2
3 20.8% of COVID– and 11.7% of UNA cases. The prevalence of heart failure, cancer and
4
5
6
7 diabetes was similar across all groups (Table 1).
8
9

10 Fewer cases among COVID+ individuals had a shockable rhythm (17.3%), compared with
11
12
13 COVID– (24.9%) and UNA (27.0%). Likewise, fewer cases among COVID+ (22.7%) were
14
15
16
17 defibrillated, compared with COVID– (31.5%) and UNA (32.8%). COVID+ cases were
18
19
20
21 ventilated in 54.8% of cases before rescue team arrival, as compared with 63.2% and 69.2%
22
23
24 in COVID– and UNA, respectively.
25
26
27

28 **Follow-up and**

29
30 Return of spontaneous circulation (ROSC) after initial resuscitation, was less common in
31
32
33 COVID+ cases, as compared with COVID– and UNA. Also, angiography, PCI, pacemaker
34
35
36
37 and ICD implantation post cardiac arrest were less common in COVID+ cases.
38
39
40
41
42
43
44

45 **Sex specific characteristics**

46
47
48 Acute myocardial infarction was observed in 21.2% of COVID+ women and 7.6% of
49
50
51 COVID+ men. Previous myocardial infarction was observed in 4.7% of COVID+ women and
52
53
54 16.2% of COVID+ men. The prevalence of previous stroke, renal failure, heart failure, cancer
55
56
57
58 and diabetes were similar among men and women, as was location at the time of cardiac
59
60

1
2
3 arrest. COVID+ men were more likely to have a shockable rhythm (20.8%) compared with
4
5
6 COVID+ women (11.5%) and to be defibrillated (26.4% in men vs 16.9% in women)
7
8
9
10 (Supplementary Table 1).
11
12

13 14 **Monthly trends in COVID-19 associated IHCA**

15
16 In March, April and May 14%, 23% and 20% of patients suffering IHCA were COVID+ (data
17
18 from 16th March). The proportion of COVID+ cases diminished rapidly during June to July.
19
20
21 From September onwards the COVID+ cases increased again to reach 19% in December. In
22
23
24
25
26
27 Figure 1A additional details regarding monthly variations are presented.
28
29
30

31 **Etiology of IHCA**

32
33 The most common cause of IHCA among COVID+ was respiratory insufficiency (24%,
34
35 n=24). The second most common cause was sepsis or other infection (19%, n=19) among
36
37
38 COVID+. Respiratory insufficiency and sepsis/other infection were less common in the other
39
40
41
42
43
44
45
46
47
48 groups (Figure 1B), which instead displayed higher rates of acute myocardial infarction.
49

48 **Clinical conditions one hour prior to IHCA**

49
50 As evident in Figure 1C which describes the clinical conditions preceding (up to 60 minutes)
51
52
53
54 the cardiac arrest, hypoxia was more common among COVID+ (57%), as compared with
55
56
57
58
59
60

1
2
3 COVID– (34%). Regarding arrhythmia, heart failure, hypotension and seizure the percentages
4
5
6
7 were more similar.
8
9

10 11 **Survival analysis** 12

13 The Kaplan Meier plots (Figure 2) show that COVID+ cases generally had a lower
14
15
16 probability of survival compared to COVID– and UNA cases. The overall 30-day survival
17
18
19 (Figure 2A) was 21% among COVID+, compared with 36% in COVID– cases ($p=0.00086$).
20
21
22

23 The subgroup analysis of women (Figure 2B) showed low survival rates in COVID+ cases
24
25
26 (16% 30-day survival). The subgroup analysis of men (Figure 2C) showed low survival rates
27
28
29 in COVID+ cases (23% 30-day survival) but not as low as the women. Regarding age, 30
30
31
32 days survival among COVID+ aged >70 years was 18% (Figure 2D), as compared with 25%
33
34
35 of COVID+ cases aged 70 or younger (Figure 2E). Survival curves for the subgroups of
36
37
38 individuals with cancer, heart failure and diabetes, did not display any clear patterns (Figure
39
40
41
42
43 2F-2H). All p values were >0.1. Patients with kidney failure had a 30 days survival of 13%
44
45
46 among COVID+ cases (Figure 2I). Patients with acute MI had a 30 days survival of 8%
47
48
49 among COVID+ cases (Figure 2J).
50
51
52
53
54
55
56
57
58
59
60

1
2
3 Cox adjusted survival curves are presented in Supplementary Figure 5; COVID+ cases
4
5
6
7 displayed the lowest probability of survival, whereas there was no material difference
8
9
10 between COVID- and UNA cases.
11
12

13 **Odds ratios for 30-days survival**

14
15
16 When adjusted for age, sex and initial rhythm the odds ratio for 30-day survival, comparing
17
18
19 COVID+ vs. COVID-, were 0.50 (0.33-0.76) overall, 0.53 (0.31-0.88) for men, and 0.44
20
21
22 (0.20-0.88) for women. In the subgroup of patients with heart failure, myocardial infarction
23
24
25
26 and cancer, we found no statistically significant associations, whereas in the subgroup of
27
28
29 COVID+ patients with kidney failure, odds ratio for 30-days survival was 0.43 (0.16-0.99),
30
31
32 when compared with COVID- (Figure 3).
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Predictors of survival

Regarding predictors for 30-days survival among COVID+ we note that confidence intervals were generally wide. Lack of ECG monitoring and later start of CPR showed point estimates below 1.0, although non-significant. Odds ratio for patients treated in non-monitored wards was 0.26 (95% CI 0.08-0.78) as compared with monitored ward(Figure 4). No coexisting condition was associated with survival among COVID+ cases.

Regarding COVID- cases the factors that were significantly associated with 30-days survival were shockable rhythm (OR 4.18 [95% CI 2.69–6.02]), ECG monitoring (2.67 [95% CI 1.82–3.95]), heart failure (OR 0.58 [95% CI 0.40–0.83]) and diabetes (OR 0.64 [95% CI 0.44–0.92]) were significantly associated with death(Figure 4).

Discussion

This study elucidates characteristics and outcomes in patients with COVID-19 who develop IHCA. As of writing this report the pandemic is still surging worldwide with hundreds of thousands of new cases every day, despite successful vaccinations efforts. We show that the prevalence of COVID-19 among patients suffering an IHCA increased to approximately one in four cardiac arrests during the first pandemic wave, and one in five cardiac arrests during the second wave. Non-respiratory and non-infectious causes are dominating the cause of

1
2
3 cardiac arrest in COVID+ patients, and probability of survival at 30-days is halved by the
4
5
6
7 presence of COVID-19.
8
9

10 Regarding location of CA, we note that the most common location for COVID-19 patients
11
12
13
14 was regular wards, which are not monitored. This is unfortunate since our analyses showed
15
16
17 that type of ward (monitored vs non-monitored) was significantly associated with survival,
18
19
20 such that COVID+ cases in non-monitored wards displayed 74% lower probability of survival
21
22
23 as compared with COVID+ cases in monitored wards. As compared with COVID- cases,
24
25
26
27 cardiac arrest in the ER was more common in COVID+ cases. The often rapid deterioration of
28
29
30 cardiopulmonary function in patients with COVID-19 may be one of the explanations for this
31
32
33 finding. Fewer COVID+ cases were located in the CCU which is an expected finding due to
34
35
36
37 the fact that cardiac etiology was less common among these patients.
38
39
40

41 We note that the most common cause of cardiac arrest in COVID+ cases, as well as the most
42
43
44 frequent clinical condition directly preceding the arrest, is respiratory. The high rate of
45
46
47 respiratory etiology was driven by men (Supplementary Figure 6-7). A total of 57% of cases
48
49
50 displayed hypoxia before cardiac arrest. This may highlight an opportunity for improving
51
52
53 outcomes; measures to prevent hypoxia and to correct it immediately may reduce the risk of
54
55
56
57 cardiac arrest in patients with COVID-19. On the other hand, it can be argued that we cannot
58
59
60

1
2
3 do that inference because we have not studied patients with and without hypoxia and followed
4
5
6 them in terms of risk of developing cardiac arrest (all our cases had already developed cardiac
7
8
9
10 arrest). However, we know that COVID-19 causes ARDS (acute respiratory distress
11
12
13 syndrome) and hypoxia, which can induce cardiac arrest.
14
15
16
17
18
19
20

21 However, the fact that 43% of cases with COVID-19 did not have hypoxia prior to cardiac
22
23
24 arrest suggests that other factors are important as well. Thromboembolism, myocardial
25
26
27 infarction, arrhythmias, etc. may all contribute to the development of a cardiac arrest(12).
28
29
30

31 A previous study from Wuhan showed that 87.5% of COVID+ cases with IHCA had a
32
33
34 respiratory etiology and a study from Southwest Georgia that 53% of the patients with IHCA
35
36
37 and COVID-19 had ARDS(5, 7). We report much lower rates of respiratory etiology (24%),
38
39
40
41 which may be due to several factors; e.g. in our study we had a total of 22 possible categories
42
43
44 for cause of CA, as compared with two categories in the study from Wuhan. Also, patients in
45
46
47 the study from Wuhan had severe COVID-19 and in our study population we do not know the
48
49
50
51 severity of the disease.
52
53
54
55

56 The survival rates were poor among COVID+ patients with an overall 30-days survival of
57
58
59 21%, compared to 36% among COVID-. The survival rate was, however, not as low as in the
60

1
2
3 study from Wuhan, in which 3% (151 patients studied) survived, or in the study from New
4
5
6 York with 31 patients or in the study from Southwest Georgia with 63 patients with none
7
8
9
10 surviving (5, 7, 13). One reason for the poor survival could be the small number of patients
11
12
13 found in a shockable rhythm (17% vs. 25% for COVID+ and COVID–, respectively) since
14
15
16 patients with shockable rhythm have a more favorable outcome. After adjusting for sex, age
17
18
19 and shockable rhythm the 30-day survival was though still significantly worse among patients
20
21
22
23 with an ongoing infection.
24
25

26
27 We demonstrate that COVID+ women had halved chance of survival at 30 days, compared
28
29
30 with COVID– women. We find it interesting that COVID+ women had acute MI three times
31
32
33 as often as men, despite the fact that men exhibited shockable rhythm – and were defibrillated
34
35
36 – twice as often as women; this cannot be explained by differences in prevalent heart failure,
37
38
39 as there were none across men and women.
40
41
42
43

44 **Strengths and limitations.** This study includes all IHCA in Sweden which were reported to
45
46
47 SRCR. The sample recorded in the SRCR is unbiased since all hospitals participate in the
48
49
50 registry and all hospitals report data on COVID-19 status. However, we do not know the
51
52
53 severity of the COVID-19 infection, and we do not know if COVID-19 was the main reason
54
55
56 for admission to hospital. With regards to the classification of COVID-19 status, we have
57
58
59
60

1
2
3 performed a misclassification analysis which demonstrated that odds ratios were not
4
5
6
7 materially affected by misclassification bias. Our study only includes IHCA's receiving CPR.
8
9
10 This leaves out all other patients with IHCA, e.g with a Do Not Attempt Resuscitation order.
11
12
13
14 It is important to stress the fact that our regression model that included only COVID-19 cases
15
16
17 must be interpreted with caution due to the large number of predictors in the model, which
18
19
20 had relatively few patients (resulting in wide confidence intervals). Further studies are
21
22
23 warranted, using a larger study population, and a longer follow up especially regarding
24
25
26 subgroup analyses, neurological outcomes and the quality of life for the patients. Information
27
28
29 about the severity of COVID-19 and the reason for admission to the hospital would add
30
31
32 valuable insights as well.
33
34
35
36
37

38 **Conclusion**

39
40
41 During pandemic peaks, up to one fourth of all IHCA's are complicated by COVID-19, and
42
43
44 these patients have halved chance of survival, with women displaying the worst outcomes.
45
46
47
48 The Pandemic has changed the whole world and the halved chance of survival displays just a
49
50
51 little part of how it has affected us all.
52
53
54
55
56
57
58
59
60

Funding

This work was supported by the Swedish Research Council [2019-02019] and the Swedish Heart and Lung Foundation [20200261].

Conflict of interest: none declared.

Author Statement: Astrid Holm and Araz Rawshani designed the study. Astrid Holm wrote the first draft of the manuscript, analyzed all data and made initial interpretations of data.

Araz Rawshani has been supervising. Matilda Jerkeman, Pedram Sultanian, Peter Lundgren, Annica Ravn-Fischer, Johan Israelsson, Jasna Giesecke and Johan Herlitz revised the article critically for important intellectual content and approved the version of the article to be published.

Ethics statement: The study was approved by the Swedish Ethical Review Authority (ID 2020-02017). The data was anonymized before the authors accessed it for the purpose of the study.

Data sharing plan: No additional data available

References

1. Johns Hopkins University and Medicine COVID-19 map [internet] Johns Hopkins Coronavirus Resource Centre 2020. [updated 13/5/2021. Available from: <https://coronavirus.jhu.edu/map.html>.
2. Dödsorsaker första halvåret 2020. Socialstyrelsen. Hälsa- och sjukvård.; 2020 17/11/2020.
3. Andersson J. Samhällsspridning av coronaviruset i Sverige. Läkartidningen. 16/03/2020.
4. Hayek SS, Brenner SK, Azam TU, Shadid HR, Anderson E, Berlin H, et al. In-hospital cardiac arrest in critically ill patients with covid-19: multicenter cohort study. *Bmj*. 2020;371:m3513.
5. Shah P, Smith H, Olarewaju A, Jani Y, Cobb A, Owens J, et al. Is Cardiopulmonary Resuscitation Futile in Coronavirus Disease 2019 Patients Experiencing In-Hospital Cardiac Arrest? *Crit Care Med*. 2021;49(2):201-8.
6. Mitchell OJL, Yuriditsky E, Johnson NJ, Doran O, Buckler DG, Neefe S, et al. In-hospital cardiac arrest in patients with coronavirus 2019. *Resuscitation*. 2021;160:72-8.
7. Shao F, Xu S, Ma X, Xu Z, Lyu J, Ng M, et al. In-hospital cardiac arrest outcomes among patients with COVID-19 pneumonia in Wuhan, China. *Resuscitation*. 2020;151:18-23.
8. Sultanian P, Lundgren P, Strömsöe A, Aune S, Bergström G, Hagberg E, et al. Cardiac arrest in COVID-19: characteristics and outcomes of in- and out-of-hospital cardiac arrest. A report from the Swedish Registry for Cardiopulmonary Resuscitation. *European Heart Journal*. 2021.
9. Hessulf F, Herlitz J, Rawshani A, Aune S, Israelsson J, Södersved-Källestedt ML, et al. Adherence to guidelines is associated with improved survival following in-hospital cardiac arrest. *Resuscitation*. 2020;155:13-21.
10. Stef van Buuren, Groothuis-Oudshoorn K. mice: Multivariate Imputation by Chained Equations in R. *Journal of Statistical Software*. 2011;Vol 45.
11. 3.5 Classification and regression trees [Available from: <https://stefvanbuuren.name/fimd/sec-cart.html>.
12. Gupta A, Madhavan MV, Sehgal K, Nair N, Mahajan S, Sehrawat TS, et al. Extrapulmonary manifestations of COVID-19. *Nat Med*. 2020;26(7):1017-32.
13. Sheth V, Chishti I, Rothman A, Redlener M, Liang J, Pan D, et al. Outcomes of in-hospital cardiac arrest in patients with COVID-19 in New York City. *Resuscitation*. 2020;155:3-5.

Table 1 Characteristics of 1613 patients with IHCA during the COVID-19 pandemic.

Variables	No infection COVID –	Ongoing infection COVID +	Unknown/NA UNA	SMD
n	1062	182	369	
Demographics:				
Age - mean (SD)	71.00 (13.32)	70.93 (12.43)	70.22 (13.60)	0.039
Woman - n (%)	388 (36.6)	68 (37.6)	151 (41.0)	0.061
Location of cardiac arrest - n (%)				
Coronary care unit - n (%)	155 (14.6)	14 (7.7)	50 (13.6)	
Intensive care unit - n (%)	77 (7.3)	25 (13.7)	19 (5.1)	
Operational room - n (%)	22 (2.1)	0 (0.0)	12 (3.3)	
Emergency room - n (%)	139 (13.1)	29 (15.9)	65 (17.6)	
Outpatient lab, radiology - n (%)	49 (4.6)	7 (3.8)	28 (7.6)	
Cathlab - n (%)	98 (9.2)	8 (4.4)	60 (16.3)	
Intermediate care unit - n (%)	25 (2.4)	15 (8.2)	10 (2.7)	
Regular ward - n (%)	468 (44.1)	82 (45.1)	116 (31.4)	
Other - n (%)	29 (2.7)	2 (1.1)	9 (2.4)	
Critical times - median (IQR):				
Time to alert – median (IQR)	1.00 [1.00, 1.00]	1.00 [1.00, 1.00]	1.00 [1.00, 1.00]	0.078
Time to CPR - median (IQR)	0.00 [0.00, 1.00]	0.00 [0.00, 0.00]	0.00 [0.00, 1.00]	0.109
Time to defibrillation - median (IQR)	2.00 [1.00, 5.00]	2.00 [1.00, 4.75]	1.00 [1.00, 4.00]	0.141
Comorbidities - n (%):				
MI, ongoing - n (%)	178 (23.6)	12 (12.0)	37 (29.4)	0.292
MI, previous - n (%)	163 (20.8)	13 (11.7)	26 (18.4)	0.165
Stroke, ongoing - n (%)	30 (3.8)	4 (3.7)	4 (3.0)	0.030
Stroke, previous - n (%)	82 (10.3)	7 (6.1)	15 (10.5)	0.105
Cancer, any - n (%)	165 (20.9)	20 (17.7)	28 (20.6)	0.054
Diabetes - n (%)	224 (27.9)	36 (31.0)	38 (27.0)	0.060
Heart failure - n (%)	229 (29.7)	36 (33.0)	36 (27.9)	0.074
Ejection fraction (%) - mean (SD)	46.14 (13.74)	46.44 (11.86)	44.94 (14.82)	0.073
EF <50% - n (%)	167 (46.0)	26 (48.1)	22 (46.8)	0.029
Kidney function category - n (%)				
eGFR <30 - n (%)	165 (21.6)	22 (20.0)	26 (20.0)	
eGFR 30–59- n (%)	216 (28.3)	32 (29.1)	44 (33.8)	
eGFR 60–89 - n (%)	198 (25.9)	25 (22.7)	30 (23.1)	
eGFR ≥90 - n (%)	185 (24.2)	31 (28.2)	30 (23.1)	
No kidney failure (eGFR ≥60) - n (%)	383 (50.1)	56 (50.9)	60 (46.2)	0.063
eGFR (ml/min/m2) - mean (SD)	66.89 (49.43)	71.26 (58.96)	63.78 (40.31)	0.099
Cause of arrest: - n (%)				
Hemorrhage - n (%)	34 (4.9)	2 (2.0)	10 (8.1)	
Myocardial infarction/ischemia- n (%)	181 (26.2)	15 (14.9)	41 (33.3)	

infarction/ischemi a	181 (26.2)	15 (14.9)	4 (33.3)				
Other - n (%)	213 (30.8)	30 (29.7)	41 (33.3)				
Primary arrhythmia - n (%)	101 (14.6)	8 (7.9)	12 (9.8)				
Respiratory insufficiency - n (%)	73 (10.5)	24 (23.8)	7 (5.7)				
Sepsis/infection - n (%)	45 (6.5)	19 (18.8)	4 (3.3)				
Stroke/thromboembolism - n (%)	45 (6.5)	3 (3.0)	8 (6.5)				
Early interventions - n (%):							
Witnessed arrest - n (%)	857 (80.9)	140 (77.8)	306 (85.0)	0.124			
ECG monitoring - n (%)	635 (60.5)	89 (50.0)	221 (62.1)	0.163			
CPR before AGA - n (%)	845 (91.0)	146 (93.6)	268 (88.2)	0.127			
Defibrillated before AGA - n (%)	159 (17.9)	18 (11.9)	53 (19.0)	0.131			
Ventilated before AGA - n (%)	503 (63.2)	74 (54.8)	175 (69.2)	0.199			
Shockable rhythm - n (%)	247 (24.9)	29 (17.3)	90 (27.0)	0.158			
Defibrillated, any - n (%)	323 (31.5)	40 (22.7)	111 (32.8)	0.151			
Intubated - n (%)	473 (47.0)	100 (57.8)	177 (53.8)	0.145			
Adrenaline given - n (%)	668 (65.6)	125 (72.7)	223 (66.4)	0.102			
Antiarrhythmics - n (%)	139 (14.1)	17 (10.1)	48 (15.4)	0.107			
Mechanical compressions - n (%)	109 (10.8)	18 (10.4)	66 (20.0)	0.180			
Active temperature control - n (%)	54 (11.3)	5 (10.4)	3 (4.4)	0.173			
Status at rescue team arrival - n (%):							
Consciousness - n (%)	214 (23.1)	18 (11.7)	57 (19.3)	0.204			
Breathing - n (%)	288 (31.2)	30 (19.5)	84 (28.7)	0.181			
Pulse - n (%)	309 (33.8)	36 (23.4)	89 (30.4)	0.154			
Follow-Up data - n (%):							
Angiography - n (%)	115 (24.2)	8 (16.7)	15 (20.8)	0.124			
PCI - n (%)	87 (18.2)	4 (8.3)	16 (21.9)	0.258			
Pacemaker implanted - n (%)	80 (16.7)	2 (4.2)	4 (5.6)	0.281			
ICD implanted - n (%)	36 (7.5)	1 (2.1)	2 (2.8)	0.172			
ROSC - n (%)	520 (49.0)	64 (35.2)	142 (38.5)	0.188			
Death at 30 days - n (%)	666 (62.7)	141 (77.5)	237 (64.2)	0.218			
Death overall - n (%)	703 (66.2)	141 (77.5)	241 (65.3)	0.181			

1
2
3
4 **SD = standard deviation; IQR = interquartile range; SMD = standardized mean difference (difference between**
5 **the means for the two groups divided by their mutual standard deviation. Values below 0.1 (10%) are**
6 **considered inconsequential (i.e., no significant difference between the groups)). CPR = Cardiopulmonary**
7 **resuscitation, PCI = Percutaneous Coronary Intervention, ICD = implantable cardioverter-defibrillator. ROSC =**
8 **return of spontaneous circulation. AGA= alarm group arrival**
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Figure Titles and Legends

Figure 1: Characteristics of IHCA according to COVID-19 status

A: Monthly proportion of COVID-19 status among patients with IHCA, stratified on COVID-19 status. In March only cases after 15/03/2020 were included.

B: Etiology of IHCA, stratified on COVID-19 status. The y-axis shows percentages for each etiology in each group.

C: Clinical conditions 1 hour prior to IHCA, stratified on COVID-19 status. Only patients with data regarding the specific condition was included.

Figure 2: Kaplan Meier survival curves

Kaplan Meier survival curves, separately for (A)Overall, (B)Women, (C)Men, (D)Age ≥ 70 year, (E)Age < 70 year, (F)Cancer, (G)Heart failure, (H)Diabetes, (I)Kidney failure and (J)Myocardial infarction. $p = \log$ -rank p -value. The numbers under the graphs are showing the survival in percentages. Regarding myocardial infarction acute MI is presented.

Figure 3: Odds Ratio for 30-day survival

Forest plot with the adjusted odds ratio for 30-day survival among patients with ongoing infection vs. no infection and unknown/NA vs. no infection. Stratified on overall, men,

1
2
3 women, age < 70 years, age ≥ 70 years, heart failure, kidney failure, diabetes, myocardial
4
5
6 infarction and cancer. Myocardial infarction was defined as acute or previous MI.
7
8
9

10 **Figure 4: Odds Ratio for 30-day survival**

11
12
13
14 Forest plot with odds ratio for 30-day survival, stratified on the groups, no infection, ongoing
15
16
17 infection and overall, all in different colors. The 95% Confidence interval is shown between
18
19
20 the bars. X-axis has a logarithmic scale. ECG=electrocardiogram, CA=cardiac arrest,
21
22
23
24
25 MI=myocardial infarction. CI=confidence interval.
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Figure 1: Characteristics of IHCA according to COVID-19 status




Figure 1A: Monthly proportion of COVID-19 status among patients with IHCA, stratified on COVID-19 status. In March only cases after 15/03/2020 were included.

Figure 1B: Etiology of IHCA, stratified on COVID-19 status. The y-axis shows percentages for each etiology in each group.

Figure 1C: Clinical conditions 1 hour prior to IHCA, stratified on COVID-19 status. Only patients with data regarding the specific condition was included.

Figure 2: Kaplan Meier survival curves




Figure 2: Kaplan Meier survival curves, separately for (A) Overall, (B) Women, (C) Men, (D) Age ≥70 year, (E) Age <70 year, (F) Cancer, (G) Heart failure, (H) Diabetes, (I) Kidney failure and (J) Myocardial infarction. p= log-rank p-value. The numbers under the graphs are showing the survival in percentages. Regarding myocardial infarction acute MI is

Figure 3: Odds Ratio for 30-day survival




Figure 3: Forest plot with the adjusted odds ratio for 30-day survival among patients with ongoing infection vs. no infection and unknown/NA vs. no infection. Stratified on overall, men, women, age < 70 years, age ≥ 70 years, heart failure, kidney failure, diabetes, myocardial infarction and cancer. Myocardial infarction was defined as acute or previous MI.

Figure 4: Odds Ratio for 30-day survival



Figure 4: Forest plot with odds ratio for 30-day survival, stratified on the groups, no infection, ongoing infection and overall, all in different colors. The 95% Confidence interval is shown between the bars. X-axis has a logarithmic scale. ECG= electrocardiogram, CA= cardiac arrest, MI= myocardial infarction. CI= confidence interval.

1
2
3
4 **Supplementary figures and tables**
5

6
7 **Characteristics and Outcomes in Patients**
8 **with COVID-19 and In-Hospital Cardiac**
9 **Arrest**
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Supplementary Table 1: Characteristics of COVID+ patients with IHCA in relation to sex.


Supplementary Table 1: Characteristics of 181 COVID+ patients with IHCA during the COVID-19 pandemic in relation to sex. One COVID+ patient had missing data on sex.

variables	Men	Women	SMD
n	113	68	
Demographics:			
Age - mean (SD)	71.39 (10.75)	70.35 (14.87)	0.080
Location of cardiac arrest - n (%):			0.249
Coronary care unit	7 (6.2)	7 (10.3)	
Intensive care unit	15 (13.3)	10 (14.7)	
Operational room	0 (0.0)	0 (0.0)	
Emergency room	17 (15.0)	11 (16.2)	
Outpatient lab, radiology	4 (3.5)	3 (4.4)	
Cathlab	6 (5.3)	2 (2.9)	
Intermediate care unit	11 (9.7)	4 (5.9)	
Regular ward	52 (46.0)	30 (44.1)	
Other	1 (0.9)	1 (1.5)	
Critical times - median (IQR):			
Time to alert – median (IQR)	1.00 [1.00, 1.00]	1.00 [1.00, 1.00]	0.256
Time to CPR - median (IQR)	0.00 [0.00, 0.00]	0.00 [0.00, 1.00]	0.031
Time to defibrillation - median	2.00 [1.00, 5.00]	2.00 [1.00, 2.00]	0.009
Comorbidities - n (%):			
MI, ongoing - n (%)	5 (7.6)	7 (21.2)	0.396
MI, previous - n (%)	11 (16.4)	2 (4.7)	0.391
Stroke, ongoing - n (%)	4 (5.8)	0 (0.0)	0.351
Stroke, previous - n (%)	5 (7.0)	2 (4.7)	0.102
Cancer, any - n (%)	13 (18.8)	6 (14.0)	0.132
Diabetes - n (%)	24 (33.3)	12 (27.9)	0.118
Heart failure - n (%)	23 (33.8)	13 (32.5)	0.028
Ejection fraction (%) - mean (SD)	44.84 (12.22)	49.31 (10.56)	0.392
EF <50% - n (%)	19 (51.4)	7 (43.8)	0.153
Kidney function category - n (%):			0.357
eGFR <30	16 (22.9)	6 (15.0)	
eGFR 30–59	17 (24.3)	15 (37.5)	
eGFR 60–89	18 (25.7)	7 (17.5)	
eGFR ≥90	19 (27.1)	12 (30.0)	
No kidney failure (eGFR ≥60)	37 (52.9)	19 (47.5)	0.107
eGFR (ml/min/m ²) - mean (SD)	72.72 (65.75)	68.70 (45.34)	0.071
Cause of arrest - n (%):			0.920
Hemorrhage	1 (1.5)	1 (2.9)	
Myocardial infarction/ischemia	7 (10.6)	8 (23.5)	
Other	18 (27.3)	12 (35.3)	
Primary arrhythmia	3 (4.5)	5 (14.7)	
Respiratory insufficiency	17 (25.8)	7 (20.6)	

Sepsis / infection	18 (27.3)	1 (2.9)	
Stroke / thromboembolism	2 (3.0)	0 (0.0)	
Early interventions - n (%):			
Witnessed arrest - n (%)	86 (76.8)	53 (79.1)	0.056
ECG monitoring - n (%)	56 (50.5)	33 (50.0)	0.009
CPR before AGA - n (%)	90 (92.8)	55 (94.8)	0.085
Defibrillated before AGA - n (%)	13 (13.8)	5 (8.9)	0.155
Ventilated before AGA- n (%)	49 (56.3)	25 (53.2)	0.063
Shockable rhythm - n (%)	22 (20.8)	7 (11.5)	0.254
Defibrillated, any - n (%)	29 (26.4)	11 (16.9)	0.231
Intubated - n (%)	61 (57.0)	38 (58.5)	0.029
Adrenaline given - n (%)	76 (70.4)	48 (76.2)	0.132
Antiarrhythmics - n (%)	11 (10.4)	6 (9.7)	0.023
Mechanical compressions - n (%)	12 (10.9)	5 (8.1)	0.097
Active temperature control - n (%)	2 (6.1)	3 (20.0)	0.423
Status at rescue team arrival - n			
Consciousness - n (%)	11 (11.3)	6 (10.7)	0.020
Breathing - n (%)	18 (18.6)	11 (19.6)	0.028
Pulse - n (%)	22 (22.7)	13 (23.2)	0.013
Follow-Up data - n (%):			
Angiography - n (%)	4 (12.1)	4 (26.7)	0.374
PCI - n (%)	2 (6.1)	2 (13.3)	0.248
Pacemaker implanted - n (%)	0 (0.0)	2 (13.3)	0.555
ICD implanted - n (%)	0 (0.0)	1 (6.7)	0.378
ROSC - n (%)	40 (35.4)	24 (35.3)	0.002
Death at 30 days - n (%)	85 (75.2)	56 (82.4)	0.175
Death overall - n (%)	85 (75.2)	56 (82.4)	0.175
Discharged alive - n (%)	16 (22.2)	6 (14.0)	0.216


SD = standard deviation; IQR = interquartile range; SMD = standardized mean difference (difference between the means for the two groups divided by their mutual standard deviation. Values below 0.1 (10%) are considered inconsequential (i.e., no significant difference between the groups)). CPR = cardiopulmonary resuscitation, PCI = percutaneous coronary intervention, ICD = implantable cardioverter-defibrillator. ROSC = return of spontaneous circulation. AGA= alarm group arrival.

Supplementary Figure 1: Missing data before and after imputation with MICE




Supplementary Figure 1: Missing data before and after imputation with MICE. A graphical view of the entire dataset is printed. Each column (variable) is depicted at the top and column color depicts type of variable. Each patient represents a row and white gaps indicate a missing data entry.

Supplementary Figure 2: Flow chart




Supplementary Figure 2: Flow chart of the study population. Patients who were less than 18 year of age, and cases occurring in the pre-pandemic period were excluded.

Supplementary Figure 3: Information on COVID-19 status during the study period.




Supplementary Figure 3: Information on COVID-19 status during the study period. No equals missing data, i.e. no information on COVID-19 status available. Yes equals, COVID +, COVID – or Unknown. In March only cases after 15/03/2020 were included.

Supplementary Figure 4: Distribution of age




Supplementary Figure 4: Distribution of age in relation to COVID-19 status.

Supplementary Figure 5: Etiology of IHCA, according to sex




Supplementary Figure 5A: Etiology of IHCA, men only.




Supplementary Figure 5B: Etiology of IHCA, women only.

Supplementary Figure 6: Conditions preceding IHCA, according to sex




Supplementary Figure 6A: Conditions preceding IHCA, men only.



Supplementary Figure 6B: Conditions preceding IHCA, women only.

Supplementary Figure 7: Cox adjusted survival curve for the overall population



Supplementary Figure 7: Cox adjusted survival curve for the overall population, stratified on COVID-19 status.

STROBE Statement—checklist of items that should be included in reports of observational studies

	Item No	Recommendation	Page No
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	1
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	2-3
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	2
Objectives	3	State specific objectives, including any prespecified hypotheses	2
Methods			
Study design	4	Present key elements of study design early in the paper	2
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	2
Participants	6	(a) <i>Cohort study</i> —Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up <i>Case-control study</i> —Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls <i>Cross-sectional study</i> —Give the eligibility criteria, and the sources and methods of selection of participants	2
		(b) <i>Cohort study</i> —For matched studies, give matching criteria and number of exposed and unexposed <i>Case-control study</i> —For matched studies, give matching criteria and the number of controls per case	2
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	5-6
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	5
Bias	9	Describe any efforts to address potential sources of bias	3-4
Study size	10	Explain how the study size was arrived at	5
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	5-6
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	6-7
		(b) Describe any methods used to examine subgroups and interactions	6-7
		(c) Explain how missing data were addressed	6-7
		(d) <i>Cohort study</i> —If applicable, explain how loss to follow-up was addressed <i>Case-control study</i> —If applicable, explain how matching of cases and controls was addressed <i>Cross-sectional study</i> —If applicable, describe analytical methods taking account of sampling strategy	6-7
		(e) Describe any sensitivity analyses	6-7

Continued on next page

Results			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	7
		(b) Give reasons for non-participation at each stage	7
		(c) Consider use of a flow diagram	Supplementary material
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	7-8
		(b) Indicate number of participants with missing data for each variable of interest	7-8
		(c) <i>Cohort study</i> —Summarise follow-up time (eg, average and total amount)	7
Outcome data	15*	<i>Cohort study</i> —Report numbers of outcome events or summary measures over time	8-9
		<i>Case-control study</i> —Report numbers in each exposure category, or summary measures of exposure	
		<i>Cross-sectional study</i> —Report numbers of outcome events or summary measures	
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	7-10
		(b) Report category boundaries when continuous variables were categorized	
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	Supplementary material
Discussion			
Key results	18	Summarise key results with reference to study objectives	11
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	13-14
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	11-14
Generalisability	21	Discuss the generalisability (external validity) of the study results	14
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	14

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.

For peer review only

BMJ Open

A Cohort Study of the Characteristics and Outcomes in Patients with COVID-19 and In-Hospital Cardiac Arrest

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2021-054943.R2
Article Type:	Original research
Date Submitted by the Author:	08-Nov-2021
Complete List of Authors:	<p>Holm, Astrid; University of Gothenburg, Department of Molecular and Clinical Medicine Jerkeman, Matilda; University of Gothenburg, Department of Molecular and Clinical Medicine Sultanian, Pedram; University of Gothenburg, Department of Molecular and Clinical Medicine Lundgren, Peter; University of Gothenburg, Department of Molecular and Clinical Medicine; Kalmar County Hospital, Department of Internal Medicine Ravn-Fischer, Annica; University of Gothenburg, Department of Molecular and Clinical Medicine Israelsson, Johan; Kalmar County Hospital, Department of Internal Medicine; Linnaeus University, Faculty of Health and Life Sciences Giesecke, Jasna; Danderyd University Hospital Herlitz, Johan; University of Borås, Centre for Prehospital Research Rawshani, Araz; University of Gothenburg, Department of Molecular and Clinical Medicine</p>
Primary Subject Heading:	Cardiovascular medicine
Secondary Subject Heading:	Cardiovascular medicine, Infectious diseases
Keywords:	COVID-19, CARDIOLOGY, Adult cardiology < CARDIOLOGY, Coronary heart disease < CARDIOLOGY

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

A Cohort Study of the Characteristics and Outcomes in Patients with COVID-19 and In-Hospital Cardiac Arrest

Astrid Holm, MD¹, Matilda Jerkeman, MD¹, Pedram Sultanian, MD¹, Peter Lundgren, MD, PhD^{1,3,7}, Annica Ravn-Fischer, MD, PhD, Docent¹, Johan Israelsson, PhD^{3,4}, Jasna Giesecke, RN⁵, Johan Herlitz, MD, PhD^{2,6}, Araz Rawshani, MD, PhD^{1,2}

Affiliations:

¹Department of Molecular and Clinical Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Sweden

²The Swedish Registry for Cardiopulmonary Resuscitation, Centre of Registries, Västra Götaland County, Sweden

³Department of Internal Medicine, Division of Cardiology, Kalmar County Hospital, Region Kalmar County, Sweden

⁴Faculty of Health and Life Sciences, Linnaeus University, Kalmar, Sweden

⁵RN, Lead CPR coordinator, Clinicum- Centre for clinical skills, interprofessional education and advanced medical simulation, Danderyd University Hospital, Stockholm, Sweden

⁶Prehospen – Centre for Prehospital Research, University of Borås, Borås, Sweden

⁷Region Västra Götaland, Sahlgrenska University Hospital, Department of Cardiology, Gothenburg, Sweden

Contact information:

Astrid Holm

Email: astrid.holm@gu.se

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Phone: +358 400707722

Manuscript word count: 3052

Abstract

Objective: We studied characteristics, survival, causes of cardiac arrest, conditions preceding cardiac arrest, predictors of survival, and trends in the prevalence of COVID-19 among in-hospital cardiac arrest (IHCA) cases.

Design and setting: Registry-based observational study.

Participants: We studied all cases (≥ 18 years of age) of IHCA receiving cardiopulmonary resuscitation (CPR) in the Swedish Registry for Cardiopulmonary Resuscitation during 15/03/2020 to 31/12/2020. A total of 1613 patients were included and divided into the following groups: ongoing infection (**COVID+**; n=182), no infection (**COVID-**; n=1062) and unknown/not assessed (**UNA**; n=369).

Main outcomes and measures: We studied monthly trends in proportions of COVID-19 associated IHCAs, causes of IHCA in relation to COVID-19 status, clinical conditions preceding the cardiac arrest and predictors of survival.

Results: The rate of COVID+ patients suffering an IHCA increased to 23% during the first pandemic wave (April), then abated to 3% in July, and then increased to 19% during the second wave (December). Among COVID+ cases, 43% had respiratory insufficiency or

1
2
3 infection as the underlying cause of the cardiac arrest, compared to 18% among COVID–
4
5
6 cases. The most common clinical sign preceding cardiac arrest was hypoxia (57%) among
7
8
9
10 COVID+ cases. Odds ratio for 30-day survival for COVID+ cases was 0.50 (95% CI 0.33–
11
12
13 0.76), compared with COVID– cases.

14
15
16
17 **Conclusion:** During pandemic peaks, up to one fourth of all IHCAs are complicated by
18
19
20 COVID-19, and these patients have halved chance of survival, with women displaying the
21
22
23
24 worst outcomes.
25
26
27
28

29 **Article Summary**

30 31 32 33 34 35 **Strengths and limitations of this study**

- 36
37
38
39 ● This study includes all IHCAs in Sweden reported to the Swedish Registry for
40
41
42 Cardiopulmonary Resuscitation. All hospitals throughout Sweden report IHCA cases
43
44
45 to the registry.
46
47
48
- 49
50 ● This study has detailed data regarding cardiac arrest parameters, including
51
52
53 circumstances before arrest, resuscitation efforts, post-resuscitation care and survival.
54
55
56 The study only includes cases in whom CPR attempts were deemed clinically
57
58
59 justified.
60

- Despite the nationwide coverage of the registry, we identified only 182 COVID positive patients, and a large number of patients had unknown COVID status.

Introduction

The COVID-19 pandemic has, as of Nov 6st 2021, infected over 249 million individuals and lead to the death of over 5 million individuals (1). COVID-19 is now the third leading cause of death in Sweden (2, 3). Multiple studies have demonstrated that in-hospital cardiac arrest (IHCA) among patients with COVID-19 is associated with poor survival (4-7). A recent study demonstrated that hypoxia was the main cause of cardiac arrest among 40% of patients with COVID-19 and IHCA (6).

We have previously reported on COVID-19 and IHCA in the Swedish Registry for Cardiopulmonary Resuscitation (SRCR), showing a 2.3-fold increase in 30-day mortality among cases with COVID-19, compared to pre-pandemic cases. This was mainly driven by a 9-fold increase in mortality among women with COVID-19. At the time, no case of IHCA with COVID-19 had been discharged alive (8). The current study expands our previous investigation, including more patients, longer follow-up and emphasizes on the causes of cardiac arrest, predictors of survival, coexisting conditions, and trends in the prevalence of COVID-19 among IHCA cases.

Methods

Data sources

This study is a registry-based observational study with data obtained from the SRCR during the time period 15/03/2020 to 31/12/2020. The SRCR is a national quality registry and has included IHCA cases since 2005. The data is collected by trained nurses who report patient data using a web-based protocol. The registry has previously been described in detail (9).

Vital status was obtained from the Swedish Population Registry and the last day of follow up was 31/12/2020.

Study population

The study population included all patients ≥ 18 years of age suffering IHCA and receiving CPR throughout Sweden during the period 15/03/2020 to 31/12/2020. We used 15th of March as the start date of the pandemic as the Swedish Public Health Authority declared on March 16th 2020 that community spread had commenced (3). On 1st of April the SRCR started collecting data regarding COVID-19 status, and retrospectively identified 60 patients with COVID-19 who suffered IHCA during March (they were included in the study). Patients were divided into the following three groups: ongoing infection (COVID+; n=182), no infection (COVID-; n=1062) and unknown/not assessed (UNA; n=369). COVID+ was defined as patients registered with an ongoing COVID-19 infection, suspected ongoing infection or

1
2
3 patients with a recent infection (n=29). The UNA group was included in the study in order to
4
5
6
7 provide a complete picture of cases enrolled in the SRCR during the time period, and to
8
9
10 evaluate whether missingness in COVID-19 status could entail selection bias.
11
12
13

14 **Variable definitions**

15
16 In SRCR a patient with cardiac arrest was defined as an unconscious patient with no or
17
18
19
20 abnormal breathing, in whom resuscitation or defibrillation was attempted. IHCA was defined
21
22
23
24 as cardiac arrest in patients admitted to the hospital.
25
26

27 With regards to previous coexisting conditions, heart failure was defined as any heart failure
28
29
30 described before cardiac arrest. Kidney failure was defined as estimated glomerular filtration
31
32
33
34 rate (eGFR) below 60 ml/min/1.73 m², calculated using the highest creatinine before cardiac
35
36
37
38 arrest with Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula. The
39
40
41 SRCR records data on the highest creatinine levels analyzed up to six months prior to CA.
42
43

44 Diabetes was defined as any diabetes diagnosis, regardless of type. Cancer was defined as any
45
46
47
48 previously known cancer. Acute myocardial infarction (MI) was defined as an MI within 72
49
50
51 hours of CA. Previous myocardial infarction was defined as MI occurring earlier than 72
52
53
54 hours preceding the CA.
55
56
57
58
59
60

1
2
3 Regarding clinical conditions one hour prior to CA, arrhythmia was defined as any
4
5
6
7 arrhythmia, hypoxia was defined as an oxygen saturation below 90%, hypotension was
8
9
10 defined as systolic blood pressure below 90 mmHg, seizure was defined as any seizure with
11
12
13 loss of consciousness, and heart failure was defined as any heart failure with pulmonary
14
15
16 edema or severe shortness of breath with rales.
17
18

19
20 Wards with monitoring included the coronary care unit (CCU), intensive care unit (ICU),
21
22
23 operating room (OR), emergency room (ER), high dependency unit (HDU) or the
24
25
26 catheterization laboratory.
27
28

29 30 31 **Statistical analyses** 32

33 Patient characteristics are reported in means and medians, along with standard deviations and
34
35
36 interquartile ranges, respectively. The Kaplan-Meier estimator was used for describing
37
38
39 survival distributions; the log rank test was used to test for differences in survival. Trends in
40
41
42 rates of COVID-19 were assessed on a monthly basis during the entire study basis.
43
44
45

46
47 Logistic regression was used to calculate odds ratios for 30-days survival. These models
48
49
50 assessed the association between COVID-19 status and 30-days survival, adjusting for age,
51
52
53 sex and initial rhythm (shockable or non-shockable). We performed subgroup analyses in
54
55
56 relation to sex, age and coexisting conditions (heart failure, cancer, diabetes, kidney failure
57
58
59
60

1
2
3 and myocardial infarction). These subgroup analyses served to clarify whether the association
4
5
6
7 between COVID status and survival was modified by age, sex or coexisting conditions.
8
9

10 In order to obtain estimates of overall survival, we used Cox proportional hazards model with
11
12
13
14 hours since CA as the time scale. The proportional hazards assumption was fulfilled for all
15
16
17
18 variables.
19

20
21 We used the MICE (Multiple Imputation By Chained Equations) algorithm to impute missing
22
23
24
25 values (10, 11) (Supplementary Figure 1). The imputed data set was used to calculate odds
26
27
28 ratios for 30-days survival in the overall group, as well as in COVID+ and COVID- cases.
29

30
31 These models included age, sex, initial rhythm, time to start of cardiopulmonary resuscitation
32
33
34 (CPR), time of CA, previous MI, type of ward, heart failure, ECG monitoring, diabetes and
35
36
37
38 acute MI.
39

40
41
42 Analyses were done in R (v. 4.0.3, R Foundation for Statistical Computing) using RStudio.
43
44
45

46 **Patient and Public Involvement statement:**

47

48 No patients were involved.
49
50
51
52
53

54 **Results**

55

56 A total of 2,227 patients were enrolled in the SRCR between 01/01/2020 and 31/12/2020.
57
58
59

60 After excluding patients <18 years (n=68) and pre-pandemic cases (n=546), 1,613 cases

1
2
3 remained from 15/03/2020 to 31/12/2020 and constituted the final study population

4
5
6
7 (Supplementary Figure 2). There was a high rate of information on COVID-19 status during

8
9
10 the study period among patients registered in the registry (Supplementary Figure 3).

11 12 13 14 **Baseline characteristics**

15
16 The overall mean age was 70.8 years, and the proportion of women was 37.6%. At the end of

17
18
19 follow-up, 341 (32.7%) patients were alive. The mean age was similar in the three groups:

20
21
22
23 70.9 years in COVID+, 71.0 years in COVID– cases, and 70.2 years in cases with UNA

24
25
26 (Supplementary Figure 4). The proportion of women was also similar; 37.6% in COVID+ and

27
28
29
30 36.6% in COVID– and 41.0% in UNA cases.

31
32
33
34 A regular ward was the most common place for cardiac arrest in all 3 groups; 45.1% of

35
36
37 COVID+, 44.1% of COVID– and 31.4% of UNA cases occurred in regular wards (Table 1).

38
39
40 The emergency room (ER) was the second most common location for COVID+ cases

41
42
43
44 (15.9%).

45
46
47 Regarding comorbidities, acute myocardial infarction was observed in 12.0% of COVID+ and

48
49
50
51 23.6% of COVID– cases. Previous myocardial infarction was observed in 11.7% of COVID+,

52
53
54 20.8% of COVID– and 11.7% of UNA cases. The prevalence of heart failure, cancer and

55
56
57
58 diabetes was similar across all groups (Table 1).

1
2
3 Fewer cases among COVID+ individuals had a shockable rhythm (17.3%), compared with
4
5
6 COVID- (24.9%) cases. Likewise, fewer cases among COVID+ (22.7%) were defibrillated,
7
8
9
10 compared with COVID- cases (31.5%). COVID+ cases were ventilated in 54.8% of cases
11
12
13 before rescue team arrival, as compared with 63.2% in COVID- cases.
14
15

16 17 **Follow-up**

18
19
20 Return of spontaneous circulation (ROSC) after initial resuscitation, was less common in
21
22
23 COVID+ cases, as compared with COVID- cases. Also, angiography, PCI, pacemaker and
24
25
26 ICD implantation post cardiac arrest were less common in COVID+ cases.
27
28
29
30
31
32
33
34

35 **Sex specific characteristics**

36
37 Acute myocardial infarction was observed in 21.2% of COVID+ women and 7.6% of
38
39
40 COVID+ men. Previous myocardial infarction was observed in 4.7% of COVID+ women and
41
42
43 16.2% of COVID+ men. The prevalence of previous stroke, renal failure, heart failure, cancer
44
45
46 and diabetes were similar among men and women, as was location at the time of cardiac
47
48
49
50
51 arrest. COVID+ men were more likely to have a shockable rhythm (20.8%) compared with
52
53
54 COVID+ women (11.5%), and to be defibrillated (26.4% in men vs. 16.9% in women)
55
56
57 (Supplementary Table 1).
58
59
60

Monthly trends in COVID-19 associated IHCA

In March, April and May 14%, 23% and 20% of patients suffering IHCA were COVID+ (data from 16th March). The proportion of COVID+ cases diminished rapidly during June to July. From September onwards the COVID+ cases increased again to reach 19% in December. In Figure 1A additional details regarding monthly variations are presented.

Etiology of IHCA

The most common cause of IHCA among COVID+ cases was respiratory insufficiency (24%, n=24), and the second most common cause was sepsis or other infection (19%, n=19).

Respiratory insufficiency and sepsis/other infection were less common in the other groups (Figure 1B), which instead displayed higher rates of acute myocardial infarction.

Clinical conditions one hour prior to IHCA

As evident in Figure 1C, which describes the clinical conditions preceding (up to 60 minutes) the cardiac arrest, hypoxia was more common among COVID+ cases (57%), as compared with COVID- cases (34%).

Survival analysis

The Kaplan Meier plots (Figure 2) show that COVID+ cases generally had a lower probability of survival compared to both COVID- and UNA cases. The overall 30-day survival (Figure 2A) was 21% among COVID+, compared with 36% in COVID- cases

1
2
3 (p=0.00086). The subgroup analysis of women (Figure 2B) showed low survival rates in
4
5
6 COVID+ cases (16% 30-day survival). The subgroup analysis of men (Figure 2C) showed
7
8
9 low survival rates in COVID+ cases (23% 30-day survival). The 30 days survival among
10
11
12 COVID+ aged >70 years was 18% (Figure 2D), as compared with 25% of COVID+ cases
13
14
15 aged 70 years or younger (Figure 2E). Survival curves for the subgroups of individuals with
16
17
18 cancer, heart failure and diabetes, did not display any distinct patterns (Figure 2F-2H), with
19
20
21 all p values >0.1. Patients with kidney failure had a 30 days survival of 13% among COVID+
22
23
24 cases (Figure 2I). Patients with acute MI had a 30 days survival of 8% among COVID+ cases
25
26
27
28 (Figure 2J).

29
30
31
32
33
34 Cox adjusted survival curves are presented in Supplementary Figure 5; COVID+ cases
35
36
37 displayed the lowest probability of survival, whereas there was no material difference
38
39
40
41 between COVID- and UNA cases.

42 43 44 **Odds ratios for 30-days survival**

45
46
47 When adjusted for age, sex and initial rhythm the odds ratios for 30-day survival, comparing
48
49
50 COVID+ vs. COVID-, were 0.50 (0.33-0.76) overall, 0.53 (0.31-0.88) for men, and 0.44
51
52
53 (0.20-0.88) for women. In the subgroup of patients with heart failure, myocardial infarction
54
55
56 and cancer, we found no statistically significant associations, whereas in the subgroup of
57
58
59
60

1
2
3 COVID+ patients with kidney failure, odds ratio for 30-days survival was 0.43 (0.16–0.99),
4
5
6
7 when compared with COVID– cases (Figure 3).
8
9

10 11 **Predictors of survival** 12

13 Regarding predictors of 30-days survival among COVID+ we note that confidence intervals
14
15
16 were generally wide. Lack of ECG monitoring and delayed start of CPR showed point
17
18
19 estimates below 1.0, although non-significant. Odds ratio for patients treated in non-
20
21
22 monitored wards was 0.26 (95% CI 0.08-0.78) as compared with monitored wards (Figure 4).
23
24
25
26
27 No coexisting condition was associated with survival among COVID+ cases.
28
29

30
31 Among COVID– cases, the factors that were significantly associated with 30-days survival
32
33
34 were shockable rhythm (OR 4.18 [95% CI 2.69–6.02]), ECG monitoring (2.67 [95% CI 1.82–
35
36
37 3.95]), heart failure (OR 0.58 [95% CI 0.40–0.83]) and diabetes (OR 0.64 [95% CI 0.44–
38
39
40
41 0.92]; Figure 4).
42
43
44
45

46 47 **Discussion** 48

49 This study elucidates characteristics and outcomes in patients with COVID-19 who develop
50
51
52 IHCA. We show that the prevalence of COVID-19 among patients suffering an IHCA
53
54
55 increased to approximately one in four cardiac arrests during the first pandemic wave, and
56
57
58
59
60

1
2
3 one in five cardiac arrests during the second wave. In IHCA the probability of survival to 30-
4
5
6
7 days is halved by the presence of COVID-19.
8
9

10 Regarding location of CA, we note that the most common location for COVID+ patients was
11
12
13
14 regular wards, which are not monitored. This is unfortunate since our analyses showed that
15
16
17 type of ward (monitored vs non-monitored) was significantly associated with survival, such
18
19
20 that COVID+ cases in non-monitored wards displayed 74% lower probability of survival as
21
22
23 compared with COVID+ cases in monitored wards. As compared with COVID- cases,
24
25
26
27 cardiac arrest in the ER was more common in COVID+ cases. The often rapid deterioration of
28
29
30 cardiopulmonary function in patients with COVID-19 may be one of the explanations for this
31
32
33 finding. Fewer COVID+ cases were located in the CCU, which was an expected finding given
34
35
36
37 that cardiac etiology was less common among these patients.
38
39
40

41 We note that the most common cause of cardiac arrest in COVID+ cases, as well as the most
42
43
44 frequent clinical condition directly preceding the arrest, was respiratory. A total of 57% of
45
46
47 cases displayed hypoxia before cardiac arrest. This may highlight an opportunity for
48
49
50 improving outcomes; measures to prevent hypoxia and to correct it immediately may reduce
51
52
53 the risk of cardiac arrest in patients with COVID-19. The high rate of respiratory etiology was
54
55
56 driven by men (Supplementary Figure 6-7).
57
58
59
60

1
2
3 However, the fact that 43% of cases with COVID-19 did not have hypoxia prior to cardiac
4
5
6
7 arrest suggests that other factors are important as well. Thromboembolism, myocardial
8
9
10 infarction, arrhythmias, etc. may all contribute to the development of a cardiac arrest (12).

11
12
13
14 A previous study from Wuhan showed that 87.5% of COVID+ cases with IHCA had a
15
16
17 respiratory etiology and a study from Southwest Georgia that 53% of the patients with IHCA
18
19
20 and COVID-19 had ARDS (5, 7).

21
22
23
24 The survival rates were poor among COVID+ patients with an overall 30-days survival of
25
26
27 21%, compared to 36% among COVID-. The survival rate was, however, not as low as in the
28
29
30 study from Wuhan, in which 3% (151 patients studied) survived, or in the study from New
31
32
33 York with 31 patients or in the study from Southwest Georgia with 63 patients with none
34
35
36 surviving (5, 7, 13). One reason for the poor survival could be the small number of patients
37
38
39 found in shockable rhythm (17% vs. 25% for COVID+ and COVID-, respectively) since
40
41
42 patients with shockable rhythm have a more favorable outcome. After adjusting for sex, age
43
44
45 and shockable rhythm the 30-day survival was still significantly worse among patients with
46
47
48 an ongoing infection.
49
50
51
52

53
54
55 We demonstrate that COVID+ women had halved chance of survival at 30 days, compared
56
57
58 with COVID- women. We find it interesting that COVID+ women had acute MI three times
59
60

1
2
3 as often as men, despite the fact that men exhibited shockable rhythm – and were defibrillated
4
5
6
7 – twice as often as women.
8
9

10 **Strengths and limitations.** This study includes all IHCA in Sweden which were reported to
11
12
13
14 SRCR. The sample recorded in the SRCR is unbiased since all hospitals participate in the
15
16
17 registry and all hospitals report data on COVID-19 status. However, we do not know the
18
19
20 severity of the COVID-19 infection, and we do not know if COVID-19 was the main reason
21
22
23 for admission to hospital. With regards to the classification of COVID-19 status, we have
24
25
26 performed a misclassification analysis which demonstrated that odds ratios were not
27
28
29 materially affected by misclassification bias. Missingness was prevalent with regards to cause
30
31
32 of cardiac arrest, which is due to the difficulties determining this factor. However, we find no
33
34
35 reason to believe that missingness differs across COVID status categories, and it should
36
37
38 therefore not bias our inferences. Our study only includes IHCA receiving CPR. This leaves
39
40
41 out all other patients with IHCA, e.g with a Do Not Attempt Resuscitation order.
42
43
44

45
46
47 Our regression models that included only COVID-19 cases should be interpreted with caution
48
49
50 due to the large number of predictors in the model, with relatively few patients (resulting in
51
52
53 wide confidence intervals). Further studies are warranted, using a larger study population, and
54
55
56
57
58
59
60

1
2
3 a longer follow up especially regarding subgroup analyses, neurological outcomes and the
4
5
6
7 quality of life for these patients.
8
9

10 **Conclusion**

11
12
13
14 During pandemic peaks, up to one fourth of all IHCA's are complicated by COVID-19, and
15
16
17 these patients have halved chance of survival, with women displaying the worst outcomes.
18
19
20
21
22

23 **Funding**

24
25
26
27 This work was supported by the Swedish Research Council [2019-02019] and the Swedish
28
29
30 Heart and Lung Foundation [20200261].
31
32
33
34

35 **Conflict of interest:** none declared.
36
37
38

39 **Author Statement:** Astrid Holm and Araz Rawshani designed the study. Astrid Holm wrote
40
41
42 the first draft of the manuscript, analyzed all data and made initial interpretations of data.
43
44
45

46 Araz Rawshani has been supervising. Matilda Jerkeman, Pedram Sultanian, Peter Lundgren,
47
48

49 Annica Ravn-Fischer, Johan Israelsson, Jasna Giesecke and Johan Herlitz revised the article
50
51

52 critically for important intellectual content and approved the version of the article to be
53
54
55

56 published.
57
58
59
60

Ethics statement: The study was approved by the Swedish Ethical Review Authority (ID

2020-02017). The data was anonymized before the authors accessed it for the purpose of the study.

Data sharing plan: No additional data available

References

1. Johns Hopkins University and Medicine COVID-19 map [internet] Johns Hopkins Coronavirus Resource Centre 2020. [updated 13/5/2021. Available from: <https://coronavirus.jhu.edu/map.html>.
2. Dödsorsaker första halvåret 2020. Socialstyrelsen. Hälsa- och sjukvård.; 2020 17/11/2020.
3. Andersson J. Samhällsspridning av coronaviruset i Sverige. Läkartidningen. 16/03/2020.
4. Hayek SS, Brenner SK, Azam TU, Shadid HR, Anderson E, Berlin H, et al. In-hospital cardiac arrest in critically ill patients with covid-19: multicenter cohort study. *Bmj*. 2020;371:m3513.
5. Shah P, Smith H, Olarewaju A, Jani Y, Cobb A, Owens J, et al. Is Cardiopulmonary Resuscitation Futile in Coronavirus Disease 2019 Patients Experiencing In-Hospital Cardiac Arrest? *Crit Care Med*. 2021;49(2):201-8.
6. Mitchell OJL, Yuriditsky E, Johnson NJ, Doran O, Buckler DG, Neefe S, et al. In-hospital cardiac arrest in patients with coronavirus 2019. *Resuscitation*. 2021;160:72-8.
7. Shao F, Xu S, Ma X, Xu Z, Lyu J, Ng M, et al. In-hospital cardiac arrest outcomes among patients with COVID-19 pneumonia in Wuhan, China. *Resuscitation*. 2020;151:18-23.
8. Sultanian P, Lundgren P, Strömsöe A, Aune S, Bergström G, Hagberg E, et al. Cardiac arrest in COVID-19: characteristics and outcomes of in- and out-of-hospital cardiac arrest. A report from the Swedish Registry for Cardiopulmonary Resuscitation. *European Heart Journal*. 2021.
9. Hessulf F, Herlitz J, Rawshani A, Aune S, Israelsson J, Södersved-Källestedt ML, et al. Adherence to guidelines is associated with improved survival following in-hospital cardiac arrest. *Resuscitation*. 2020;155:13-21.
10. Stef van Buuren, Groothuis-Oudshoorn K. mice: Multivariate Imputation by Chained Equations in R. *Journal of Statistical Software*. 2011;Vol 45.
11. 3.5 Classification and regression trees [Available from: <https://stefvanbuuren.name/fimd/sec-cart.html>.
12. Gupta A, Madhavan MV, Sehgal K, Nair N, Mahajan S, Sehrawat TS, et al. Extrapulmonary manifestations of COVID-19. *Nat Med*. 2020;26(7):1017-32.
13. Sheth V, Chishti I, Rothman A, Redlener M, Liang J, Pan D, et al. Outcomes of in-hospital cardiac arrest in patients with COVID-19 in New York City. *Resuscitation*. 2020;155:3-5.

Table 1 Characteristics of 1613 patients with IHCA during the COVID-19 pandemic.

Variables	No infection COVID –	Ongoing infection COVID +	Unknown/NA UNA	SMD
n	1062	182	369	
Demographics:				
Age - mean (SD)	71.00 (13.32)	70.93 (12.43)	70.22 (13.60)	0.039
Woman - n (%)	388 (36.6)	68 (37.6)	151 (41.0)	0.061
Location of cardiac arrest - n (%)				0.527
Coronary care unit - n (%)	155 (14.6)	14 (7.7)	50 (13.6)	
Intensive care unit - n (%)	77 (7.3)	25 (13.7)	19 (5.1)	
Operational room - n (%)	22 (2.1)	0 (0.0)	12 (3.3)	
Emergency room - n (%)	139 (13.1)	29 (15.9)	65 (17.6)	
Outpatient lab, radiology - n (%)	49 (4.6)	7 (3.8)	28 (7.6)	
Cathlab - n (%)	98 (9.2)	8 (4.4)	60 (16.3)	
Intermediate care unit - n (%)	25 (2.4)	15 (8.2)	10 (2.7)	
Regular ward - n (%)	468 (44.1)	82 (45.1)	116 (31.4)	
Other - n (%)	29 (2.7)	2 (1.1)	9 (2.4)	
Critical times - median (IQR):				
Time to alert – median (IQR)	1.00 [1.00, 1.00]	1.00 [1.00, 1.00]	1.00 [1.00, 1.00]	0.078
Time to CPR - median (IQR)	0.00 [0.00, 1.00]	0.00 [0.00, 0.00]	0.00 [0.00, 1.00]	0.109
Time to defibrillation - median (IQR)	2.00 [1.00, 5.00]	2.00 [1.00, 4.75]	1.00 [1.00, 4.00]	0.141
Comorbidities - n (%):				
MI, ongoing - n (%)	178 (23.6)	12 (12.0)	37 (29.4)	0.292
MI, previous - n (%)	163 (20.8)	13 (11.7)	26 (18.4)	0.165
Stroke, ongoing - n (%)	30 (3.8)	4 (3.7)	4 (3.0)	0.030
Stroke, previous - n (%)	82 (10.3)	7 (6.1)	15 (10.5)	0.105
Cancer, any - n (%)	165 (20.9)	20 (17.7)	28 (20.6)	0.054
Diabetes - n (%)	224 (27.9)	36 (31.0)	38 (27.0)	0.060
Heart failure - n (%)	229 (29.7)	36 (33.0)	36 (27.9)	0.074
Ejection fraction (%) - mean (SD)	46.14 (13.74)	46.44 (11.86)	44.94 (14.82)	0.073
EF <50% - n (%)	167 (46.0)	26 (48.1)	22 (46.8)	0.029
Kidney function category - n (%)				0.121
eGFR <30 - n (%)	165 (21.6)	22 (20.0)	26 (20.0)	
eGFR 30–59 - n (%)	216 (28.3)	32 (29.1)	44 (33.8)	
eGFR 60–89 - n (%)	198 (25.9)	25 (22.7)	30 (23.1)	
eGFR ≥90 - n (%)	185 (24.2)	31 (28.2)	30 (23.1)	
No kidney failure (eGFR ≥60) - n (%)	383 (50.1)	56 (50.9)	60 (46.2)	0.063
eGFR (ml/min/m ²) - mean (SD)	66.89 (49.43)	71.26 (58.96)	63.78 (40.31)	0.099
Cause of arrest: - n (%)				0.629
Hemorrhage - n (%)	34 (4.9)	2 (2.0)	10 (8.1)	
Myocardial infarction/ischemia - n (%)	181 (26.2)	15 (14.9)	41 (33.3)	

infarction/ischemi a	181 (26.2)	15 (14.9)	4 (33.3)				
Other - n (%)	213 (30.8)	30 (29.7)	41 (33.3)				
Primary arrhythmia - n (%)	101 (14.6)	8 (7.9)	12 (9.8)				
Respiratory insufficiency - n (%)	73 (10.5)	24 (23.8)	7 (5.7)				
Sepsis/infection - n (%)	45 (6.5)	19 (18.8)	4 (3.3)				
Stroke/thromboembolism - n (%)	45 (6.5)	3 (3.0)	8 (6.5)				
Early interventions - n (%):							
Witnessed arrest - n (%)	857 (80.9)	140 (77.8)	306 (85.0)	0.124			
ECG monitoring - n (%)	635 (60.5)	89 (50.0)	221 (62.1)	0.163			
CPR before AGA - n (%)	845 (91.0)	146 (93.6)	268 (88.2)	0.127			
Defibrillated before AGA - n (%)	159 (17.9)	18 (11.9)	53 (19.0)	0.131			
Ventilated before AGA - n (%)	503 (63.2)	74 (54.8)	175 (69.2)	0.199			
Shockable rhythm - n (%)	247 (24.9)	29 (17.3)	90 (27.0)	0.158			
Defibrillated, any - n (%)	323 (31.5)	40 (22.7)	111 (32.8)	0.151			
Intubated - n (%)	473 (47.0)	100 (57.8)	177 (53.8)	0.145			
Adrenaline given - n (%)	668 (65.6)	125 (72.7)	223 (66.4)	0.102			
Antiarrhythmics - n (%)	139 (14.1)	17 (10.1)	48 (15.4)	0.107			
Mechanical compressions - n (%)	109 (10.8)	18 (10.4)	66 (20.0)	0.180			
Active temperature control - n (%)	54 (11.3)	5 (10.4)	3 (4.4)	0.173			
Status at rescue team arrival - n (%):							
Consciousness - n (%)	214 (23.1)	18 (11.7)	57 (19.3)	0.204			
Breathing - n (%)	288 (31.2)	30 (19.5)	84 (28.7)	0.181			
Pulse - n (%)	309 (33.8)	36 (23.4)	89 (30.4)	0.154			
Follow-Up data - n (%):							
Angiography - n (%)	115 (24.2)	8 (16.7)	15 (20.8)	0.124			
PCI - n (%)	87 (18.2)	4 (8.3)	16 (21.9)	0.258			
Pacemaker implanted - n (%)	80 (16.7)	2 (4.2)	4 (5.6)	0.281			
ICD implanted - n (%)	36 (7.5)	1 (2.1)	2 (2.8)	0.172			
ROSC - n (%)	520 (49.0)	64 (35.2)	142 (38.5)	0.188			
Death at 30 days - n (%)	666 (62.7)	141 (77.5)	237 (64.2)	0.218			
Death overall - n (%)	703 (66.2)	141 (77.5)	241 (65.3)	0.181			

1
2
3
4 **SD = standard deviation; IQR = interquartile range; SMD = standardized mean difference (difference between**
5 **the means for the two groups divided by their mutual standard deviation. Values below 0.1 (10%) are**
6 **considered inconsequential (i.e., no significant difference between the groups)). CPR = Cardiopulmonary**
7 **resuscitation, PCI = Percutaneous Coronary Intervention, ICD = implantable cardioverter-defibrillator. ROSC =**
8 **return of spontaneous circulation. AGA= alarm group arrival**
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24

25 **Figure Titles and Legends**

26 **Figure 1: Characteristics of IHCA according to COVID-19 status**

27
28
29
30
31 A: Monthly proportion of COVID-19 status among patients with IHCA, stratified on COVID-
32
33
34
35 19 status. In March only cases after 15/03/2020 were included.
36
37

38
39 B: Etiology of IHCA, stratified on COVID-19 status. The y-axis shows percentages for each
40
41
42 etiology in each group.
43
44

45
46 C: Clinical conditions 1 hour prior to IHCA, stratified on COVID-19 status. Only patients
47
48
49 with data regarding the specific condition was included.
50
51

52 **Figure 2: Kaplan Meier survival curves**

1
2
3 Kaplan Meier survival curves, separately for (A)Overall, (B)Women, (C)Men, (D)Age ≥ 70
4
5
6
7 year, (E)Age < 70 year, (F)Cancer, (G)Heart failure, (H)Diabetes, (I)Kidney failure and
8
9
10 (J)Myocardial infarction. $p = \log$ -rank p -value. The numbers under the graphs are showing the
11
12
13 survival in percentages. Regarding myocardial infarction acute MI is presented.
14
15
16

17 **Figure 3: Odds Ratio for 30-day survival**

18
19
20
21 Forest plot with the adjusted odds ratio for 30-day survival among patients with ongoing
22
23
24 infection vs. no infection and unknown/NA vs. no infection. Stratified on overall, men,
25
26
27 women, age < 70 years, age ≥ 70 years, heart failure, kidney failure, diabetes, myocardial
28
29
30 infarction and cancer. Myocardial infarction was defined as acute or previous MI.
31
32
33
34

35 **Figure 4: Odds Ratio for 30-day survival**

36
37
38
39 Forest plot with odds ratio for 30-day survival, stratified on the groups, no infection, ongoing
40
41
42 infection and overall, all in different colors. The 95% Confidence interval is shown between
43
44
45 the bars. X-axis has a logarithmic scale. ECG=electrocardiogram, CA=cardiac arrest,
46
47
48
49 MI=myocardial infarction. CI=confidence interval.
50
51
52
53
54
55
56
57
58
59
60

Figure 1: Characteristics of IHCA according to COVID-19 status




Figure 1A: Monthly proportion of COVID-19 status among patients with IHCA, stratified on COVID-19 status. In March only cases after 15/03/2020 were included.

Figure 1B: Etiology of IHCA, stratified on COVID-19 status. The y-axis shows percentages for each etiology in each group.

Figure 1C: Clinical conditions 1 hour prior to IHCA, stratified on COVID-19 status. Only patients with data regarding the specific condition was included.

Figure 2: Kaplan Meier survival curves




Figure 2: Kaplan Meier survival curves, separately for (A) Overall, (B) Women, (C) Men, (D) Age ≥70 year, (E) Age <70 year, (F) Cancer, (G) Heart failure, (H) Diabetes, (I) Kidney failure and (J) Myocardial infarction. p= log-rank p-value. The numbers under the graphs are showing the survival in percentages. Regarding myocardial infarction acute MI is

Figure 3: Odds Ratio for 30-day survival




Figure 3: Forest plot with the adjusted odds ratio for 30-day survival among patients with ongoing infection vs. no infection and unknown/NA vs. no infection. Stratified on overall, men, women, age < 70 years, age ≥ 70 years, heart failure, kidney failure, diabetes, myocardial infarction and cancer. Myocardial infarction was defined as acute or previous MI.

Figure 4: Odds Ratio for 30-day survival



Figure 4: Forest plot with odds ratio for 30-day survival, stratified on the groups, no infection, ongoing infection and overall, all in different colors. The 95% Confidence interval is shown between the bars. X-axis has a logarithmic scale. ECG= electrocardiogram, CA= cardiac arrest, MI= myocardial infarction. CI= confidence interval.

1
2
3
4 **Supplementary figures and tables**
5

6
7 **Characteristics and Outcomes in Patients**
8 **with COVID-19 and In-Hospital Cardiac**
9 **Arrest**
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Supplementary Table 1: Characteristics of COVID+ patients with IHCA in relation to sex.


Supplementary Table 1: Characteristics of 181 COVID+ patients with IHCA during the COVID-19 pandemic in relation to sex. One COVID+ patient had missing data on sex.

variables	Men	Women	SMD
n	113	68	
Demographics:			
Age - mean (SD)	71.39 (10.75)	70.35 (14.87)	0.080
Location of cardiac arrest - n (%):			0.249
Coronary care unit	7 (6.2)	7 (10.3)	
Intensive care unit	15 (13.3)	10 (14.7)	
Operational room	0 (0.0)	0 (0.0)	
Emergency room	17 (15.0)	11 (16.2)	
Outpatient lab, radiology	4 (3.5)	3 (4.4)	
Cathlab	6 (5.3)	2 (2.9)	
Intermediate care unit	11 (9.7)	4 (5.9)	
Regular ward	52 (46.0)	30 (44.1)	
Other	1 (0.9)	1 (1.5)	
Critical times - median (IQR):			
Time to alert – median (IQR)	1.00 [1.00, 1.00]	1.00 [1.00, 1.00]	0.256
Time to CPR - median (IQR)	0.00 [0.00, 0.00]	0.00 [0.00, 1.00]	0.031
Time to defibrillation - median	2.00 [1.00, 5.00]	2.00 [1.00, 2.00]	0.009
Comorbidities - n (%):			
MI, ongoing - n (%)	5 (7.6)	7 (21.2)	0.396
MI, previous - n (%)	11 (16.4)	2 (4.7)	0.391
Stroke, ongoing - n (%)	4 (5.8)	0 (0.0)	0.351
Stroke, previous - n (%)	5 (7.0)	2 (4.7)	0.102
Cancer, any - n (%)	13 (18.8)	6 (14.0)	0.132
Diabetes - n (%)	24 (33.3)	12 (27.9)	0.118
Heart failure - n (%)	23 (33.8)	13 (32.5)	0.028
Ejection fraction (%) - mean (SD)	44.84 (12.22)	49.31 (10.56)	0.392
EF <50% - n (%)	19 (51.4)	7 (43.8)	0.153
Kidney function category - n (%):			0.357
eGFR <30	16 (22.9)	6 (15.0)	
eGFR 30–59	17 (24.3)	15 (37.5)	
eGFR 60–89	18 (25.7)	7 (17.5)	
eGFR ≥90	19 (27.1)	12 (30.0)	
No kidney failure (eGFR ≥60)	37 (52.9)	19 (47.5)	0.107
eGFR (ml/min/m ²) - mean (SD)	72.72 (65.75)	68.70 (45.34)	0.071
Cause of arrest - n (%):			0.920
Hemorrhage	1 (1.5)	1 (2.9)	
Myocardial infarction/ischemia	7 (10.6)	8 (23.5)	
Other	18 (27.3)	12 (35.3)	
Primary arrhythmia	3 (4.5)	5 (14.7)	
Respiratory insufficiency	17 (25.8)	7 (20.6)	

Sepsis / infection	18 (27.3)	1 (2.9)	
Stroke / thromboembolism	2 (3.0)	0 (0.0)	
Early interventions - n (%):			
Witnessed arrest - n (%)	86 (76.8)	53 (79.1)	0.056
ECG monitoring - n (%)	56 (50.5)	33 (50.0)	0.009
CPR before AGA - n (%)	90 (92.8)	55 (94.8)	0.085
Defibrillated before AGA - n (%)	13 (13.8)	5 (8.9)	0.155
Ventilated before AGA- n (%)	49 (56.3)	25 (53.2)	0.063
Shockable rhythm - n (%)	22 (20.8)	7 (11.5)	0.254
Defibrillated, any - n (%)	29 (26.4)	11 (16.9)	0.231
Intubated - n (%)	61 (57.0)	38 (58.5)	0.029
Adrenaline given - n (%)	76 (70.4)	48 (76.2)	0.132
Antiarrhythmics - n (%)	11 (10.4)	6 (9.7)	0.023
Mechanical compressions - n (%)	12 (10.9)	5 (8.1)	0.097
Active temperature control - n (%)	2 (6.1)	3 (20.0)	0.423
Status at rescue team arrival - n			
Consciousness - n (%)	11 (11.3)	6 (10.7)	0.020
Breathing - n (%)	18 (18.6)	11 (19.6)	0.028
Pulse - n (%)	22 (22.7)	13 (23.2)	0.013
Follow-Up data - n (%):			
Angiography - n (%)	4 (12.1)	4 (26.7)	0.374
PCI - n (%)	2 (6.1)	2 (13.3)	0.248
Pacemaker implanted - n (%)	0 (0.0)	2 (13.3)	0.555
ICD implanted - n (%)	0 (0.0)	1 (6.7)	0.378
ROSC - n (%)	40 (35.4)	24 (35.3)	0.002
Death at 30 days - n (%)	85 (75.2)	56 (82.4)	0.175
Death overall - n (%)	85 (75.2)	56 (82.4)	0.175
Discharged alive - n (%)	16 (22.2)	6 (14.0)	0.216


SD = standard deviation; IQR = interquartile range; SMD = standardized mean difference (difference between the means for the two groups divided by their mutual standard deviation. Values below 0.1 (10%) are considered inconsequential (i.e., no significant difference between the groups)). CPR = cardiopulmonary resuscitation, PCI = percutaneous coronary intervention, ICD = implantable cardioverter-defibrillator. ROSC = return of spontaneous circulation. AGA= alarm group arrival.

Supplementary Figure 1: Missing data before and after imputation with MICE




Supplementary Figure 1: Missing data before and after imputation with MICE. A graphical view of the entire dataset is printed. Each column (variable) is depicted at the top and column color depicts type of variable. Each patient represents a row and white gaps indicate a missing data entry.

Supplementary Figure 2: Flow chart



Supplementary Figure 2: Flow chart of the study population. Patients who were less than 18 year of age, and cases occurring in the pre-pandemic period were excluded.


Supplementary Figure 3: Information on COVID-19 status during the study period.



Supplementary Figure 3: Information on COVID-19 status during the study period. No equals missing data, i.e. no information on COVID-19 status available. Yes equals, COVID +, COVID – or Unknown. In March only cases after 15/03/2020 were included.


1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Supplementary Figure 4: Distribution of age




Supplementary Figure 4: Distribution of age in relation to COVID-19 status.

Supplementary Figure 5: Etiology of IHCA, according to sex




Supplementary Figure 5A: Etiology of IHCA, men only.




Supplementary Figure 5B: Etiology of IHCA, women only.

Supplementary Figure 6: Conditions preceding IHCA, according to sex




Supplementary Figure 6A: Conditions preceding IHCA, men only.



Supplementary Figure 6B: Conditions preceding IHCA, women only.

Supplementary Figure 7: Cox adjusted survival curve for the overall population



Supplementary Figure 7: Cox adjusted survival curve for the overall population, stratified on COVID-19 status.

STROBE Statement—checklist of items that should be included in reports of observational studies

	Item No	Recommendation	Page No
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	1
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	2-3
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	2
Objectives	3	State specific objectives, including any prespecified hypotheses	2
Methods			
Study design	4	Present key elements of study design early in the paper	2
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	2
Participants	6	(a) <i>Cohort study</i> —Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up <i>Case-control study</i> —Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls <i>Cross-sectional study</i> —Give the eligibility criteria, and the sources and methods of selection of participants	2
		(b) <i>Cohort study</i> —For matched studies, give matching criteria and number of exposed and unexposed <i>Case-control study</i> —For matched studies, give matching criteria and the number of controls per case	2
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	5-6
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	5
Bias	9	Describe any efforts to address potential sources of bias	3-4
Study size	10	Explain how the study size was arrived at	5
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	5-6
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	6-7
		(b) Describe any methods used to examine subgroups and interactions	6-7
		(c) Explain how missing data were addressed	6-7
		(d) <i>Cohort study</i> —If applicable, explain how loss to follow-up was addressed <i>Case-control study</i> —If applicable, explain how matching of cases and controls was addressed <i>Cross-sectional study</i> —If applicable, describe analytical methods taking account of sampling strategy	6-7
		(e) Describe any sensitivity analyses	6-7

Continued on next page

Results			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	7
		(b) Give reasons for non-participation at each stage	7
		(c) Consider use of a flow diagram	Supplementary material
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	7-8
		(b) Indicate number of participants with missing data for each variable of interest	7-8
		(c) <i>Cohort study</i> —Summarise follow-up time (eg, average and total amount)	7
Outcome data	15*	<i>Cohort study</i> —Report numbers of outcome events or summary measures over time	8-9
		<i>Case-control study</i> —Report numbers in each exposure category, or summary measures of exposure	
		<i>Cross-sectional study</i> —Report numbers of outcome events or summary measures	
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	7-10
		(b) Report category boundaries when continuous variables were categorized	
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	Supplementary material
Discussion			
Key results	18	Summarise key results with reference to study objectives	11
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	13-14
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	11-14
Generalisability	21	Discuss the generalisability (external validity) of the study results	14
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	14

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely

1
2 available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at
3 <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is
4 available at www.strobe-statement.org.
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

BMJ Open

A Cohort Study of the Characteristics and Outcomes in Patients with COVID-19 and In-Hospital Cardiac Arrest

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2021-054943.R3
Article Type:	Original research
Date Submitted by the Author:	13-Nov-2021
Complete List of Authors:	<p>Holm, Astrid; University of Gothenburg, Department of Molecular and Clinical Medicine Jerkeman, Matilda; University of Gothenburg, Department of Molecular and Clinical Medicine Sultanian, Pedram; University of Gothenburg, Department of Molecular and Clinical Medicine Lundgren, Peter; University of Gothenburg, Department of Molecular and Clinical Medicine; Kalmar County Hospital, Department of Internal Medicine Ravn-Fischer, Annica; University of Gothenburg, Department of Molecular and Clinical Medicine Israelsson, Johan; Kalmar County Hospital, Department of Internal Medicine; Linnaeus University, Faculty of Health and Life Sciences Giesecke, Jasna; Danderyd University Hospital Herlitz, Johan; University of Borås, Centre for Prehospital Research Rawshani, Araz; University of Gothenburg, Department of Molecular and Clinical Medicine</p>
Primary Subject Heading:	Cardiovascular medicine
Secondary Subject Heading:	Cardiovascular medicine, Infectious diseases
Keywords:	COVID-19, CARDIOLOGY, Adult cardiology < CARDIOLOGY, Coronary heart disease < CARDIOLOGY

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

A Cohort Study of the Characteristics and Outcomes in Patients with COVID-19 and In-Hospital Cardiac Arrest

Astrid Holm, MD¹, Matilda Jerkeman, MD¹, Pedram Sultanian, MD¹, Peter Lundgren, MD, PhD^{1,3,7}, Annica Ravn-Fischer, MD, PhD, Docent¹, Johan Israelsson, PhD^{3,4}, Jasna Giesecke, RN⁵, Johan Herlitz, MD, PhD^{2,6}, Araz Rawshani, MD, PhD^{1,2}

Affiliations:

¹Department of Molecular and Clinical Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Sweden

²The Swedish Registry for Cardiopulmonary Resuscitation, Centre of Registries, Västra Götaland County, Sweden

³Department of Internal Medicine, Division of Cardiology, Kalmar County Hospital, Region Kalmar County, Sweden

⁴Faculty of Health and Life Sciences, Linnaeus University, Kalmar, Sweden

⁵RN, Lead CPR coordinator, Clinicum- Centre for clinical skills, interprofessional education and advanced medical simulation, Danderyd University Hospital, Stockholm, Sweden

⁶Prehospiten – Centre for Prehospital Research, University of Borås, Borås, Sweden

⁷Region Västra Götaland, Sahlgrenska University Hospital, Department of Cardiology, Gothenburg, Sweden

Contact information:

Astrid Holm

Email: astrid.holm@gu.se

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Phone: +358 400707722

Manuscript word count: 3088

Abstract

Objective: We studied characteristics, survival, causes of cardiac arrest, conditions preceding cardiac arrest, predictors of survival, and trends in the prevalence of COVID-19 among in-hospital cardiac arrest (IHCA) cases.

Design and setting: Registry-based observational study.

Participants: We studied all cases (≥ 18 years of age) of IHCA receiving cardiopulmonary resuscitation (CPR) in the Swedish Registry for Cardiopulmonary Resuscitation during 15/03/2020 to 31/12/2020. A total of 1613 patients were included and divided into the following groups: ongoing infection (**COVID+**; n=182), no infection (**COVID-**; n=1062) and unknown/not assessed (**UNA**; n=369).

Main outcomes and measures: We studied monthly trends in proportions of COVID-19 associated IHCAs, causes of IHCA in relation to COVID-19 status, clinical conditions preceding the cardiac arrest and predictors of survival.

Results: The rate of COVID+ patients suffering an IHCA increased to 23% during the first pandemic wave (April), then abated to 3% in July, and then increased to 19% during the second wave (December). Among COVID+ cases, 43% had respiratory insufficiency or

1
2
3 infection as the underlying cause of the cardiac arrest, compared to 18% among COVID–
4
5
6 cases. The most common clinical sign preceding cardiac arrest was hypoxia (57%) among
7
8
9 COVID+ cases. Odds ratio for 30-day survival for COVID+ cases was 0.50 (95% CI 0.33–
10
11
12 0.76), compared with COVID– cases.
13
14
15

16
17 **Conclusion:** During pandemic peaks, up to one fourth of all IHCA are complicated by
18
19 COVID-19, and these patients have halved chance of survival, with women displaying the
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000

Article Summary

Strengths and limitations of this study

- A major strength of our study is that it includes all IHCAs in Sweden which were reported to the Swedish Registry for Cardiopulmonary Resuscitation.
- The sample recorded in the Swedish Registry for Cardiopulmonary Resuscitation is unbiased since all hospitals participate in the registry and all hospitals report data on COVID-19 status

- A limitation is that we do not know the severity of the COVID-19 infection, and we do not know if COVID-19 was the main reason for admission to hospital.
- Our study only includes IHCA's receiving CPR which leaves out all other patients with IHCA, e.g with a Do Not Attempt Resuscitation order.

Introduction

The COVID-19 pandemic has, as of Nov 6th 2021, infected over 249 million individuals and lead to the death of over 5 million individuals (1). COVID-19 is now the third leading cause of death in Sweden (2, 3). Multiple studies have demonstrated that in-hospital cardiac arrest (IHCA) among patients with COVID-19 is associated with poor survival (4-7). A recent study demonstrated that hypoxia was the main cause of cardiac arrest among 40% of patients with COVID-19 and IHCA (6).

We have previously reported on COVID-19 and IHCA in the Swedish Registry for Cardiopulmonary Resuscitation (SRCR), showing a 2.3-fold increase in 30-day mortality among cases with COVID-19, compared to pre-pandemic cases. This was mainly driven by a 9-fold increase in mortality among women with COVID-19. At the time, no case of IHCA with COVID-19 had been discharged alive (8). The current study expands our previous investigation, including more patients, longer follow-up and emphasizes on the causes of

1
2
3 cardiac arrest, predictors of survival, coexisting conditions, and trends in the prevalence of
4
5
6 COVID-19 among IHCA cases.
7
8
9

10 11 12 **Methods**

13 14 15 **Data sources**

16
17 This study is a registry-based observational study with data obtained from the SRCR during
18
19 the time period 15/03/2020 to 31/12/2020. The SRCR is a national quality registry and has
20
21 included IHCA cases since 2005. The data is collected by trained nurses who report patient
22
23 data using a web-based protocol. The registry has previously been described in detail (9).
24
25
26
27
28
29

30
31 Vital status was obtained from the Swedish Population Registry and the last day of follow up
32
33 was 31/12/2020.
34
35
36
37

38 39 **Study population**

40
41 The study population included all patients ≥ 18 years of age suffering IHCA and receiving
42
43 CPR throughout Sweden during the period 15/03/2020 to 31/12/2020. We used 15th of March
44
45 as the start date of the pandemic as the Swedish Public Health Authority declared on March
46
47
48
49
50
51 16th 2020 that community spread had commenced (3). On 1st of April the SRCR started
52
53 collecting data regarding COVID-19 status, and retrospectively identified 60 patients with
54
55
56
57 COVID-19 who suffered IHCA during March (they were included in the study). Patients were
58
59
60

1
2
3 divided into the following three groups: ongoing infection (COVID+; n=182), no infection
4
5
6 (COVID-; n=1062) and unknown/not assessed (UNA; n=369). COVID+ was defined as
7
8
9 patients registered with an ongoing COVID-19 infection, suspected ongoing infection or
10
11 patients with a recent infection (n=29). The UNA group was included in the study in order to
12
13
14 provide a complete picture of cases enrolled in the SRCR during the time period, and to
15
16
17
18 evaluate whether missingness in COVID-19 status could entail selection bias.
19
20
21
22
23

24 **Variable definitions**

25
26 In SRCR a patient with cardiac arrest was defined as an unconscious patient with no or
27
28 abnormal breathing, in whom resuscitation or defibrillation was attempted. IHCA was defined
29
30 as cardiac arrest in patients admitted to the hospital.
31
32
33

34
35 With regards to previous coexisting conditions, heart failure was defined as any heart failure
36
37 described before cardiac arrest. Kidney failure was defined as estimated glomerular filtration
38
39 rate (eGFR) below 60 ml/min/1.73 m², calculated using the highest creatinine before cardiac
40
41
42
43
44
45
46
47
48 arrest with Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula. The
49
50
51 SRCR records data on the highest creatinine levels analyzed up to six months prior to CA.
52

53
54 Diabetes was defined as any diabetes diagnosis, regardless of type. Cancer was defined as any
55
56
57 previously known cancer. Acute myocardial infarction (MI) was defined as an MI within 72
58
59
60

1
2
3 hours of CA. Previous myocardial infarction was defined as MI occurring earlier than 72
4
5
6
7 hours preceding the CA.
8
9

10 Regarding clinical conditions one hour prior to CA, arrhythmia was defined as any
11
12
13 arrhythmia, hypoxia was defined as an oxygen saturation below 90%, hypotension was
14
15
16 defined as systolic blood pressure below 90 mmHg, seizure was defined as any seizure with
17
18
19 loss of consciousness, and heart failure was defined as any heart failure with pulmonary
20
21
22 edema or severe shortness of breath with rales.
23
24
25

26 Wards with monitoring included the coronary care unit (CCU), intensive care unit (ICU),
27
28
29 operating room (OR), emergency room (ER), high dependency unit (HDU) or the
30
31
32 catheterization laboratory.
33
34
35

36 37 38 **Statistical analyses** 39

40 Patient characteristics are reported in means and medians, along with standard deviations and
41
42
43 interquartile ranges, respectively. The Kaplan-Meier estimator was used for describing
44
45
46 survival distributions; the log rank test was used to test for differences in survival. Trends in
47
48
49 rates of COVID-19 were assessed on a monthly basis during the entire study basis.
50
51
52

53
54 Logistic regression was used to calculate odds ratios for 30-days survival. These models
55
56
57 assessed the association between COVID-19 status and 30-days survival, adjusting for age,
58
59
60

1
2
3 sex and initial rhythm (shockable or non-shockable). We performed subgroup analyses in
4
5
6
7 relation to sex, age and coexisting conditions (heart failure, cancer, diabetes, kidney failure
8
9
10 and myocardial infarction). These subgroup analyses served to clarify whether the association
11
12
13 between COVID status and survival was modified by age, sex or coexisting conditions.
14

15
16
17 In order to obtain estimates of overall survival, we used Cox proportional hazards model with
18
19
20 hours since CA as the time scale. The proportional hazards assumption was fulfilled for all
21
22
23
24 variables.
25

26
27
28 We used the MICE (Multiple Imputation By Chained Equations) algorithm to impute missing
29
30
31 values (10, 11) (Supplementary Figure 1). The imputed data set was used to calculate odds
32
33
34 ratios for 30-days survival in the overall group, as well as in COVID+ and COVID- cases.
35

36
37
38 These models included age, sex, initial rhythm, time to start of cardiopulmonary resuscitation
39
40
41 (CPR), time of CA, previous MI, type of ward, heart failure, ECG monitoring, diabetes and
42
43
44 acute MI.
45

46
47
48 Analyses were done in R (v. 4.0.3, R Foundation for Statistical Computing) using RStudio.
49

50 51 52 **Patient and Public Involvement statement:**

53
54
55 No patients were involved.
56
57
58
59
60

Results

A total of 2,227 patients were enrolled in the SRCR between 01/01/2020 and 31/12/2020.

After excluding patients <18 years (n=68) and pre-pandemic cases (n=546), 1,613 cases

remained from 15/03/2020 to 31/12/2020 and constituted the final study population

(Supplementary Figure 2). There was a high rate of information on COVID-19 status during

the study period among patients registered in the registry (Supplementary Figure 3).

Baseline characteristics

The overall mean age was 70.8 years, and the proportion of women was 37.6%. At the end of

follow-up, 341 (32.7%) patients were alive. The mean age was similar in the three groups:

70.9 years in COVID+, 71.0 years in COVID– cases, and 70.2 years in cases with UNA

(Supplementary Figure 4). The proportion of women was also similar; 37.6% in COVID+ and

36.6% in COVID– and 41.0% in UNA cases.

A regular ward was the most common place for cardiac arrest in all 3 groups; 45.1% of

COVID+, 44.1% of COVID– and 31.4% of UNA cases occurred in regular wards (Table 1).

The emergency room (ER) was the second most common location for COVID+ cases

(15.9%).

1
2
3 Regarding comorbidities, acute myocardial infarction was observed in 12.0% of COVID+ and
4
5
6
7 23.6% of COVID- cases. Previous myocardial infarction was observed in 11.7% of COVID+,
8
9
10 20.8% of COVID- and 11.7% of UNA cases. The prevalence of heart failure, cancer and
11
12
13 diabetes was similar across all groups (Table 1).
14

15
16
17 Fewer cases among COVID+ individuals had a shockable rhythm (17.3%), compared with
18
19
20 COVID- (24.9%) cases. Likewise, fewer cases among COVID+ (22.7%) were defibrillated,
21
22
23 compared with COVID- cases (31.5%). COVID+ cases were ventilated in 54.8% of cases
24
25
26 before rescue team arrival, as compared with 63.2% in COVID- cases.
27
28
29

30 31 Follow-up

32
33 Return of spontaneous circulation (ROSC) after initial resuscitation, was less common in
34
35
36 COVID+ cases, as compared with COVID- cases. Also, angiography, PCI, pacemaker and
37
38
39 ICD implantation post cardiac arrest were less common in COVID+ cases.
40
41
42
43
44
45
46
47
48

49 Sex specific characteristics

50
51 Acute myocardial infarction was observed in 21.2% of COVID+ women and 7.6% of
52
53
54 COVID+ men. Previous myocardial infarction was observed in 4.7% of COVID+ women and
55
56
57 16.2% of COVID+ men. The prevalence of previous stroke, renal failure, heart failure, cancer
58
59
60

1
2
3 and diabetes were similar among men and women, as was location at the time of cardiac
4
5
6
7 arrest. COVID+ men were more likely to have a shockable rhythm (20.8%) compared with
8
9
10 COVID+ women (11.5%), and to be defibrillated (26.4% in men vs. 16.9% in women)
11
12
13 (Supplementary Table 1).
14
15
16
17

18 **Monthly trends in COVID-19 associated IHCA**

19

20 In March, April and May 14%, 23% and 20% of patients suffering IHCA were COVID+ (data
21
22
23 from 16th March). The proportion of COVID+ cases diminished rapidly during June to July.
24
25
26
27 From September onwards the COVID+ cases increased again to reach 19% in December. In
28
29
30 Figure 1A additional details regarding monthly variations are presented.
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Etiology of IHCA

The most common cause of IHCA among COVID+ cases was respiratory insufficiency (24%, n=24), and the second most common cause was sepsis or other infection (19%, n=19).

Respiratory insufficiency and sepsis/other infection were less common in the other groups (Figure 1B), which instead displayed higher rates of acute myocardial infarction.

Clinical conditions one hour prior to IHCA

As evident in Figure 1C, which describes the clinical conditions preceding (up to 60 minutes) the cardiac arrest, hypoxia was more common among COVID+ cases (57%), as compared with COVID- cases (34%).

Survival analysis

The Kaplan Meier plots (Figure 2) show that COVID+ cases generally had a lower probability of survival compared to both COVID- and UNA cases. The overall 30-day survival (Figure 2A) was 21% among COVID+, compared with 36% in COVID- cases (p=0.00086). The subgroup analysis of women (Figure 2B) showed low survival rates in COVID+ cases (16% 30-day survival). The subgroup analysis of men (Figure 2C) showed low survival rates in COVID+ cases (23% 30-day survival). The 30 days survival among COVID+ aged >70 years was 18% (Figure 2D), as compared with 25% of COVID+ cases aged 70 years or younger (Figure 2E). Survival curves for the subgroups of individuals with

1
2
3 cancer, heart failure and diabetes, did not display any distinct patterns (Figure 2F-2H), with
4
5
6
7 all p values >0.1. Patients with kidney failure had a 30 days survival of 13% among COVID+
8
9
10 cases (Figure 2I). Patients with acute MI had a 30 days survival of 8% among COVID+ cases
11
12
13 (Figure 2J).

14
15
16
17 Cox adjusted survival curves are presented in Supplementary Figure 5; COVID+ cases
18
19
20 displayed the lowest probability of survival, whereas there was no material difference
21
22
23
24 between COVID- and UNA cases.

25 26 27 **Odds ratios for 30-days survival**

28
29
30 When adjusted for age, sex and initial rhythm the odds ratios for 30-day survival, comparing
31
32
33 COVID+ vs. COVID-, were 0.50 (0.33-0.76) overall, 0.53 (0.31-0.88) for men, and 0.44
34
35
36 (0.20-0.88) for women. In the subgroup of patients with heart failure, myocardial infarction
37
38
39 and cancer, we found no statistically significant associations, whereas in the subgroup of
40
41
42
43 COVID+ patients with kidney failure, odds ratio for 30-days survival was 0.43 (0.16-0.99),
44
45
46 when compared with COVID- cases (Figure 3).

47 48 49 **Predictors of survival**

50
51
52
53 Regarding predictors of 30-days survival among COVID+ we note that confidence intervals
54
55
56 were generally wide. Lack of ECG monitoring and delayed start of CPR showed point
57
58
59
60

1
2
3 estimates below 1.0, although non-significant. Odds ratio for patients treated in non-
4
5
6 monitored wards was 0.26 (95% CI 0.08-0.78) as compared with monitored wards (Figure 4).
7
8
9

10 No coexisting condition was associated with survival among COVID+ cases.
11
12

13
14 Among COVID- cases, the factors that were significantly associated with 30-days survival
15
16 were shockable rhythm (OR 4.18 [95% CI 2.69–6.02]), ECG monitoring (2.67 [95% CI 1.82–
17
18 3.95]), heart failure (OR 0.58 [95% CI 0.40–0.83]) and diabetes (OR 0.64 [95% CI 0.44–
19
20 0.92]; Figure 4).
21
22
23
24
25
26
27
28

29 Discussion

30
31
32 This study elucidates characteristics and outcomes in patients with COVID-19 who develop
33
34
35 IHCA. We show that the prevalence of COVID-19 among patients suffering an IHCA
36
37
38 increased to approximately one in four cardiac arrests during the first pandemic wave, and
39
40
41 one in five cardiac arrests during the second wave. In IHCA the probability of survival to 30-
42
43
44 days is halved by the presence of COVID-19.
45
46
47

48
49 Regarding location of CA, we note that the most common location for COVID+ patients was
50
51
52 regular wards, which are not monitored. This is unfortunate since our analyses showed that
53
54
55 type of ward (monitored vs non-monitored) was significantly associated with survival, such
56
57
58 that COVID+ cases in non-monitored wards displayed 74% lower probability of survival as
59
60

1
2
3 compared with COVID+ cases in monitored wards. As compared with COVID– cases,
4
5
6 cardiac arrest in the ER was more common in COVID+ cases. The often rapid deterioration of
7
8
9 cardiopulmonary function in patients with COVID-19 may be one of the explanations for this
10
11
12 finding. Fewer COVID+ cases were located in the CCU, which was an expected finding given
13
14
15 that cardiac etiology was less common among these patients.
16
17
18
19

20
21 We note that the most common cause of cardiac arrest in COVID+ cases, as well as the most
22
23 frequent clinical condition directly preceding the arrest, was respiratory. A total of 57% of
24
25
26 cases displayed hypoxia before cardiac arrest. This may highlight an opportunity for
27
28
29 improving outcomes; measures to prevent hypoxia and to correct it immediately may reduce
30
31
32 the risk of cardiac arrest in patients with COVID-19. The high rate of respiratory etiology was
33
34
35 driven by men (Supplementary Figure 6-7).
36
37
38
39

40
41 However, the fact that 43% of cases with COVID-19 did not have hypoxia prior to cardiac
42
43
44 arrest suggests that other factors are important as well. Thromboembolism, myocardial
45
46
47 infarction, arrhythmias, etc. may all contribute to the development of a cardiac arrest (12).
48
49
50

51
52 A previous study from Wuhan showed that 87.5% of COVID+ cases with IHCA had a
53
54
55 respiratory etiology and a study from Southwest Georgia that 53% of the patients with IHCA
56
57
58 and COVID-19 had ARDS (5, 7).
59
60

1
2
3 The survival rates were poor among COVID+ patients with an overall 30-days survival of
4
5
6
7 21%, compared to 36% among COVID-. The survival rate was, however, not as low as in the
8
9
10 study from Wuhan, in which 3% (151 patients studied) survived, or in the study from New
11
12
13 York with 31 patients or in the study from Southwest Georgia with 63 patients with none
14
15
16 surviving (5, 7, 13). One reason for the poor survival could be the small number of patients
17
18
19 found in shockable rhythm (17% vs. 25% for COVID+ and COVID-, respectively) since
20
21
22 patients with shockable rhythm have a more favorable outcome. After adjusting for sex, age
23
24
25 and shockable rhythm the 30-day survival was still significantly worse among patients with
26
27
28 an ongoing infection.
29
30
31

32
33
34 We demonstrate that COVID+ women had halved chance of survival at 30 days, compared
35
36
37 with COVID- women. We find it interesting that COVID+ women had acute MI three times
38
39
40 as often as men, despite the fact that men exhibited shockable rhythm – and were defibrillated
41
42
43 – twice as often as women.
44
45
46
47

48 **Strengths and limitations.** This study includes all IHCA in Sweden which were reported to
49
50
51 SRCR. The sample recorded in the SRCR is unbiased since all hospitals participate in the
52
53
54 registry and all hospitals report data on COVID-19 status. However, we do not know the
55
56
57 severity of the COVID-19 infection, and we do not know if COVID-19 was the main reason
58
59
60

1
2
3 for admission to hospital. With regards to the classification of COVID-19 status, we have
4
5
6 performed a misclassification analysis which demonstrated that odds ratios were not
7
8
9
10 materially affected by misclassification bias. Missingness was prevalent with regards to cause
11
12
13 of cardiac arrest, which is due to the difficulties determining this factor. However, we find no
14
15
16 reason to believe that missingness differs across COVID status categories, and it should
17
18
19 therefore not bias our inferences. Our study only includes IHCA's receiving CPR. This leaves
20
21
22 out all other patients with IHCA, e.g with a Do Not Attempt Resuscitation order.
23
24
25
26
27 Our regression models that included only COVID-19 cases should be interpreted with caution
28
29
30 due to the large number of predictors in the model, with relatively few patients (resulting in
31
32
33 wide confidence intervals). Further studies are warranted, using a larger study population, and
34
35
36 a longer follow up especially regarding subgroup analyses, neurological outcomes and the
37
38
39 quality of life for these patients.
40
41
42
43
44

45 **Conclusion**

46
47
48 During pandemic peaks, up to one fourth of all IHCA's are complicated by COVID-19, and
49
50
51 these patients have halved chance of survival, with women displaying the worst outcomes.
52
53
54
55
56
57
58
59
60

Funding

This work was supported by the Swedish Research Council [2019-02019] and the Swedish Heart and Lung Foundation [20200261].

Conflict of interest: none declared.

Author Statement: Astrid Holm and Araz Rawshani designed the study. Astrid Holm wrote the first draft of the manuscript, analyzed all data and made initial interpretations of data.

Araz Rawshani has been supervising. Matilda Jerkeman, Pedram Sultanian, Peter Lundgren, Annica Ravn-Fischer, Johan Israelsson, Jasna Giesecke and Johan Herlitz revised the article critically for important intellectual content and approved the version of the article to be published.

Ethics statement: The study was approved by the Swedish Ethical Review Authority (ID 2020-02017). The data was anonymized before the authors accessed it for the purpose of the study.

Data sharing plan: No additional data available

References

1. Johns Hopkins University and Medicine COVID-19 map [internet] Johns Hopkins Coronavirus Resource Centre 2020. [updated 13/5/2021. Available from: <https://coronavirus.jhu.edu/map.html>.
2. Dödsorsaker första halvåret 2020. Socialstyrelsen. Hälsa- och sjukvård.; 2020 17/11/2020.
3. Andersson J. Samhällsspridning av coronaviruset i Sverige. Läkartidningen. 16/03/2020.
4. Hayek SS, Brenner SK, Azam TU, Shadid HR, Anderson E, Berlin H, et al. In-hospital cardiac arrest in critically ill patients with covid-19: multicenter cohort study. *Bmj*. 2020;371:m3513.
5. Shah P, Smith H, Olarewaju A, Jani Y, Cobb A, Owens J, et al. Is Cardiopulmonary Resuscitation Futile in Coronavirus Disease 2019 Patients Experiencing In-Hospital Cardiac Arrest? *Crit Care Med*. 2021;49(2):201-8.
6. Mitchell OJL, Yuriditsky E, Johnson NJ, Doran O, Buckler DG, Neefe S, et al. In-hospital cardiac arrest in patients with coronavirus 2019. *Resuscitation*. 2021;160:72-8.
7. Shao F, Xu S, Ma X, Xu Z, Lyu J, Ng M, et al. In-hospital cardiac arrest outcomes among patients with COVID-19 pneumonia in Wuhan, China. *Resuscitation*. 2020;151:18-23.
8. Sultanian P, Lundgren P, Strömsöe A, Aune S, Bergström G, Hagberg E, et al. Cardiac arrest in COVID-19: characteristics and outcomes of in- and out-of-hospital cardiac arrest. A report from the Swedish Registry for Cardiopulmonary Resuscitation. *European Heart Journal*. 2021.
9. Hessulf F, Herlitz J, Rawshani A, Aune S, Israelsson J, Södersved-Källestedt ML, et al. Adherence to guidelines is associated with improved survival following in-hospital cardiac arrest. *Resuscitation*. 2020;155:13-21.
10. Stef van Buuren, Groothuis-Oudshoorn K. mice: Multivariate Imputation by Chained Equations in R. *Journal of Statistical Software*. 2011;Vol 45.
11. 3.5 Classification and regression trees [Available from: <https://stefvanbuuren.name/fimd/sec-cart.html>.
12. Gupta A, Madhavan MV, Sehgal K, Nair N, Mahajan S, Sehrawat TS, et al. Extrapulmonary manifestations of COVID-19. *Nat Med*. 2020;26(7):1017-32.
13. Sheth V, Chishti I, Rothman A, Redlener M, Liang J, Pan D, et al. Outcomes of in-hospital cardiac arrest in patients with COVID-19 in New York City. *Resuscitation*. 2020;155:3-5.

Table 1 Characteristics of 1613 patients with IHCA during the COVID-19 pandemic.

Variables	No infection COVID –	Ongoing infection COVID +	Unknown/NA UNA	SMD
n	1062	182	369	
Demographics:				
Age - mean (SD)	71.00 (13.32)	70.93 (12.43)	70.22 (13.60)	0.039
Woman - n (%)	388 (36.6)	68 (37.6)	151 (41.0)	0.061
Location of cardiac arrest - n (%)				0.527
Coronary care unit - n (%)	155 (14.6)	14 (7.7)	50 (13.6)	
Intensive care unit - n (%)	77 (7.3)	25 (13.7)	19 (5.1)	
Operational room - n (%)	22 (2.1)	0 (0.0)	12 (3.3)	
Emergency room - n (%)	139 (13.1)	29 (15.9)	65 (17.6)	
Outpatient lab, radiology - n (%)	49 (4.6)	7 (3.8)	28 (7.6)	
Cathlab - n (%)	98 (9.2)	8 (4.4)	60 (16.3)	
Intermediate care unit - n (%)	25 (2.4)	15 (8.2)	10 (2.7)	
Regular ward - n (%)	468 (44.1)	82 (45.1)	116 (31.4)	
Other - n (%)	29 (2.7)	2 (1.1)	9 (2.4)	
Critical times - median (IQR):				
Time to alert – median (IQR)	1.00 [1.00, 1.00]	1.00 [1.00, 1.00]	1.00 [1.00, 1.00]	0.078
Time to CPR - median (IQR)	0.00 [0.00, 1.00]	0.00 [0.00, 0.00]	0.00 [0.00, 1.00]	0.109
Time to defibrillation - median (IQR)	2.00 [1.00, 5.00]	2.00 [1.00, 4.75]	1.00 [1.00, 4.00]	0.141
Comorbidities - n (%):				
MI, ongoing - n (%)	178 (23.6)	12 (12.0)	37 (29.4)	0.292
MI, previous - n (%)	163 (20.8)	13 (11.7)	26 (18.4)	0.165
Stroke, ongoing - n (%)	30 (3.8)	4 (3.7)	4 (3.0)	0.030
Stroke, previous - n (%)	82 (10.3)	7 (6.1)	15 (10.5)	0.105
Cancer, any - n (%)	165 (20.9)	20 (17.7)	28 (20.6)	0.054
Diabetes - n (%)	224 (27.9)	36 (31.0)	38 (27.0)	0.060
Heart failure - n (%)	229 (29.7)	36 (33.0)	36 (27.9)	0.074
Ejection fraction (%) - mean (SD)	46.14 (13.74)	46.44 (11.86)	44.94 (14.82)	0.073
EF <50% - n (%)	167 (46.0)	26 (48.1)	22 (46.8)	0.029
Kidney function category - n (%)				0.121
eGFR <30 - n (%)	165 (21.6)	22 (20.0)	26 (20.0)	
eGFR 30–59 - n (%)	216 (28.3)	32 (29.1)	44 (33.8)	
eGFR 60–89 - n (%)	198 (25.9)	25 (22.7)	30 (23.1)	
eGFR ≥90 - n (%)	185 (24.2)	31 (28.2)	30 (23.1)	
No kidney failure (eGFR ≥60) - n (%)	383 (50.1)	56 (50.9)	60 (46.2)	0.063
eGFR (ml/min/m ²) - mean (SD)	66.89 (49.43)	71.26 (58.96)	63.78 (40.31)	0.099
Cause of arrest: - n (%)				0.629
Hemorrhage - n (%)	34 (4.9)	2 (2.0)	10 (8.1)	
Myocardial infarction/ischemia - n (%)	181 (26.2)	15 (14.9)	41 (33.3)	

infarction/ischemi a	181 (26.2)	15 (14.9)	4 (33.3)				
Other - n (%)	213 (30.8)	30 (29.7)	41 (33.3)				
Primary arrhythmia - n (%)	101 (14.6)	8 (7.9)	12 (9.8)				
Respiratory insufficiency - n (%)	73 (10.5)	24 (23.8)	7 (5.7)				
Sepsis/infection - n (%)	45 (6.5)	19 (18.8)	4 (3.3)				
Stroke/thromboembolism - n (%)	45 (6.5)	3 (3.0)	8 (6.5)				
Early interventions - n (%):							
Witnessed arrest - n (%)	857 (80.9)	140 (77.8)	306 (85.0)	0.124			
ECG monitoring - n (%)	635 (60.5)	89 (50.0)	221 (62.1)	0.163			
CPR before AGA - n (%)	845 (91.0)	146 (93.6)	268 (88.2)	0.127			
Defibrillated before AGA - n (%)	159 (17.9)	18 (11.9)	53 (19.0)	0.131			
Ventilated before AGA - n (%)	503 (63.2)	74 (54.8)	175 (69.2)	0.199			
Shockable rhythm - n (%)	247 (24.9)	29 (17.3)	90 (27.0)	0.158			
Defibrillated, any - n (%)	323 (31.5)	40 (22.7)	111 (32.8)	0.151			
Intubated - n (%)	473 (47.0)	100 (57.8)	177 (53.8)	0.145			
Adrenaline given - n (%)	668 (65.6)	125 (72.7)	223 (66.4)	0.102			
Antiarrhythmics - n (%)	139 (14.1)	17 (10.1)	48 (15.4)	0.107			
Mechanical compressions - n (%)	109 (10.8)	18 (10.4)	66 (20.0)	0.180			
Active temperature control - n (%)	54 (11.3)	5 (10.4)	3 (4.4)	0.173			
Status at rescue team arrival - n (%):							
Consciousness - n (%)	214 (23.1)	18 (11.7)	57 (19.3)	0.204			
Breathing - n (%)	288 (31.2)	30 (19.5)	84 (28.7)	0.181			
Pulse - n (%)	309 (33.8)	36 (23.4)	89 (30.4)	0.154			
Follow-Up data - n (%):							
Angiography - n (%)	115 (24.2)	8 (16.7)	15 (20.8)	0.124			
PCI - n (%)	87 (18.2)	4 (8.3)	16 (21.9)	0.258			
Pacemaker implanted - n (%)	80 (16.7)	2 (4.2)	4 (5.6)	0.281			
ICD implanted - n (%)	36 (7.5)	1 (2.1)	2 (2.8)	0.172			
ROSC - n (%)	520 (49.0)	64 (35.2)	142 (38.5)	0.188			
Death at 30 days - n (%)	666 (62.7)	141 (77.5)	237 (64.2)	0.218			
Death overall - n (%)	703 (66.2)	141 (77.5)	241 (65.3)	0.181			

1
2
3
4 SD = standard deviation; IQR = interquartile range; SMD = standardized mean difference (difference between
5 the means for the two groups divided by their mutual standard deviation. Values below 0.1 (10%) are
6 considered inconsequential (i.e., no significant difference between the groups)). CPR = Cardiopulmonary
7 resuscitation, PCI = Percutaneous Coronary Intervention, ICD = implantable cardioverter-defibrillator. ROSC =
8 return of spontaneous circulation. AGA= alarm group arrival
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25

26 Figure Titles and Legends

27
28 **Figure 1: Characteristics of IHCA according to COVID-19 status**

29
30
31
32 **Figure 1A: Monthly proportion of COVID-19 status among patients with IHCA, stratified on**
33
34
35 **COVID-19 status.** In March only cases after 15/03/2020 were included.

36
37
38
39 **Figure 1B: Etiology of IHCA, stratified on COVID-19 status.** The y-axis shows percentages
40
41
42 for each etiology in each group.

43
44
45
46 **Figure 1C: Clinical conditions 1 hour prior to IHCA, stratified on COVID-19 status.** Only
47
48
49 patients with data regarding the specific condition was included.
50

51
52
53
54
55
56 **Figure 2: Kaplan Meier survival curves**
57
58
59
60

1
2
3
4 **Figure 2: Kaplan Meier survival curves**, separately for (A) Overall, (B) Women, (C) Men, (D)
5
6
7 Age ≥ 70 year, (E) Age < 70 year, (F) Cancer, (G) Heart failure, (H) Diabetes, (I) Kidney
8
9
10 failure and (J) Myocardial infarction. $p = \log$ -rank p -value. The numbers under the graphs are
11
12
13 showing the survival in percentages. Regarding myocardial infarction acute MI is presented.
14
15
16
17
18

19 **Figure 3: Odds Ratio for 30-day survival**

20
21
22
23 **Figure 3: Forest plot with the adjusted odds ratio for 30-day survival among patients with**
24
25
26 **ongoing infection vs. no infection and unknown/NA vs. no infection.** Stratified on overall,
27
28
29 men, women, age < 70 years, age ≥ 70 years, heart failure, kidney failure, diabetes,
30
31
32
33 myocardial infarction and cancer. Myocardial infarction was defined as acute or previous MI.
34
35
36
37
38
39

40 **Figure 4: Odds Ratio for 30-day survival**

41
42
43
44 **Figure 4: Forest plot with odds ratio for 30-day survival**, stratified on the groups, no
45
46 infection, ongoing infection and overall, all in different colors. The 95% Confidence interval
47
48 is shown between the bars. X-axis has a logarithmic scale. ECG= electrocardiogram, CA=
49
50 cardiac arrest, MI= myocardial infarction. CI= confidence interval.
51
52
53
54
55
56
57
58
59
60

Figure 1: Characteristics of IHCA according to COVID-19 status




Figure 1A: Monthly proportion of COVID-19 status among patients with IHCA, stratified on COVID-19 status. In March only cases after 15/03/2020 were included.

Figure 1B: Etiology of IHCA, stratified on COVID-19 status. The y-axis shows percentages for each etiology in each group.

Figure 1C: Clinical conditions 1 hour prior to IHCA, stratified on COVID-19 status. Only patients with data regarding the specific condition was included.

Figure 2: Kaplan Meier survival curves




Figure 2: Kaplan Meier survival curves, separately for (A) Overall, (B) Women, (C) Men, (D) Age ≥70 year, (E) Age <70 year, (F) Cancer, (G) Heart failure, (H) Diabetes, (I) Kidney failure and (J) Myocardial infarction. p= log-rank p-value. The numbers under the graphs are showing the survival in percentages. Regarding myocardial infarction acute MI is presented.

Figure 3: Odds Ratio for 30-day survival




Figure 3: Forest plot with the adjusted odds ratio for 30-day survival among patients with ongoing infection vs. no infection and unknown/NA vs. no infection. Stratified on overall, men, women, age < 70 years, age ≥ 70 years, heart failure, kidney failure, diabetes, myocardial infarction and cancer. Myocardial infarction was defined as acute or previous MI.

Figure 4: Odds Ratio for 30-day survival




Figure 4: Forest plot with odds ratio for 30-day survival, stratified on the groups, no infection, ongoing infection and overall, all in different colors. The 95% Confidence interval is shown between the bars. X-axis has a logarithmic scale. ECG= electrocardiogram, CA= cardiac arrest, MI= myocardial infarction. CI= confidence interval.

1
2
3
4 **Supplementary figures and tables**
5
6

7 **Characteristics and Outcomes in Patients**
8 **with COVID-19 and In-Hospital Cardiac**
9 **Arrest**
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Supplementary Table 1: Characteristics of COVID+ patients with IHCA in relation to sex.


Supplementary Table 1: Characteristics of 181 COVID+ patients with IHCA during the COVID-19 pandemic in relation to sex. One COVID+ patient had missing data on sex.

variables	Men	Women	SMD
n	113	68	
Demographics:			
Age - mean (SD)	71.39 (10.75)	70.35 (14.87)	0.080
Location of cardiac arrest - n (%):			0.249
Coronary care unit	7 (6.2)	7 (10.3)	
Intensive care unit	15 (13.3)	10 (14.7)	
Operational room	0 (0.0)	0 (0.0)	
Emergency room	17 (15.0)	11 (16.2)	
Outpatient lab, radiology	4 (3.5)	3 (4.4)	
Cathlab	6 (5.3)	2 (2.9)	
Intermediate care unit	11 (9.7)	4 (5.9)	
Regular ward	52 (46.0)	30 (44.1)	
Other	1 (0.9)	1 (1.5)	
Critical times - median (IQR):			
Time to alert – median (IQR)	1.00 [1.00, 1.00]	1.00 [1.00, 1.00]	0.256
Time to CPR - median (IQR)	0.00 [0.00, 0.00]	0.00 [0.00, 1.00]	0.031
Time to defibrillation - median	2.00 [1.00, 5.00]	2.00 [1.00, 2.00]	0.009
Comorbidities - n (%):			
MI, ongoing - n (%)	5 (7.6)	7 (21.2)	0.396
MI, previous - n (%)	11 (16.4)	2 (4.7)	0.391
Stroke, ongoing - n (%)	4 (5.8)	0 (0.0)	0.351
Stroke, previous - n (%)	5 (7.0)	2 (4.7)	0.102
Cancer, any - n (%)	13 (18.8)	6 (14.0)	0.132
Diabetes - n (%)	24 (33.3)	12 (27.9)	0.118
Heart failure - n (%)	23 (33.8)	13 (32.5)	0.028
Ejection fraction (%) - mean (SD)	44.84 (12.22)	49.31 (10.56)	0.392
EF <50% - n (%)	19 (51.4)	7 (43.8)	0.153
Kidney function category - n (%):			0.357
eGFR <30	16 (22.9)	6 (15.0)	
eGFR 30–59	17 (24.3)	15 (37.5)	
eGFR 60–89	18 (25.7)	7 (17.5)	
eGFR ≥90	19 (27.1)	12 (30.0)	
No kidney failure (eGFR ≥60)	37 (52.9)	19 (47.5)	0.107
eGFR (ml/min/m ²) - mean (SD)	72.72 (65.75)	68.70 (45.34)	0.071
Cause of arrest - n (%):			0.920
Hemorrhage	1 (1.5)	1 (2.9)	
Myocardial infarction/ischemia	7 (10.6)	8 (23.5)	
Other	18 (27.3)	12 (35.3)	
Primary arrhythmia	3 (4.5)	5 (14.7)	
Respiratory insufficiency	17 (25.8)	7 (20.6)	

Sepsis / infection	18 (27.3)	1 (2.9)	
Stroke / thromboembolism	2 (3.0)	0 (0.0)	
Early interventions - n (%):			
Witnessed arrest - n (%)	86 (76.8)	53 (79.1)	0.056
ECG monitoring - n (%)	56 (50.5)	33 (50.0)	0.009
CPR before AGA - n (%)	90 (92.8)	55 (94.8)	0.085
Defibrillated before AGA - n (%)	13 (13.8)	5 (8.9)	0.155
Ventilated before AGA- n (%)	49 (56.3)	25 (53.2)	0.063
Shockable rhythm - n (%)	22 (20.8)	7 (11.5)	0.254
Defibrillated, any - n (%)	29 (26.4)	11 (16.9)	0.231
Intubated - n (%)	61 (57.0)	38 (58.5)	0.029
Adrenaline given - n (%)	76 (70.4)	48 (76.2)	0.132
Antiarrhythmics - n (%)	11 (10.4)	6 (9.7)	0.023
Mechanical compressions - n (%)	12 (10.9)	5 (8.1)	0.097
Active temperature control - n (%)	2 (6.1)	3 (20.0)	0.423
Status at rescue team arrival - n			
Consciousness - n (%)	11 (11.3)	6 (10.7)	0.020
Breathing - n (%)	18 (18.6)	11 (19.6)	0.028
Pulse - n (%)	22 (22.7)	13 (23.2)	0.013
Follow-Up data - n (%):			
Angiography - n (%)	4 (12.1)	4 (26.7)	0.374
PCI - n (%)	2 (6.1)	2 (13.3)	0.248
Pacemaker implanted - n (%)	0 (0.0)	2 (13.3)	0.555
ICD implanted - n (%)	0 (0.0)	1 (6.7)	0.378
ROSC - n (%)	40 (35.4)	24 (35.3)	0.002
Death at 30 days - n (%)	85 (75.2)	56 (82.4)	0.175
Death overall - n (%)	85 (75.2)	56 (82.4)	0.175
Discharged alive - n (%)	16 (22.2)	6 (14.0)	0.216


SD = standard deviation; IQR = interquartile range; SMD = standardized mean difference (difference between the means for the two groups divided by their mutual standard deviation. Values below 0.1 (10%) are considered inconsequential (i.e., no significant difference between the groups)). CPR = cardiopulmonary resuscitation, PCI = percutaneous coronary intervention, ICD = implantable cardioverter-defibrillator. ROSC = return of spontaneous circulation. AGA= alarm group arrival.

Supplementary Figure 1: Missing data before and after imputation with MICE




Supplementary Figure 1: Missing data before and after imputation with MICE. A graphical view of the entire dataset is printed. Each column (variable) is depicted at the top and column color depicts type of variable. Each patient represents a row and white gaps indicate a missing data entry.

Supplementary Figure 2: Flow chart




Supplementary Figure 2: Flow chart of the study population. Patients who were less than 18 year of age, and cases occurring in the pre-pandemic period were excluded.

Supplementary Figure 3: Information on COVID-19 status during the study period.




Supplementary Figure 3: Information on COVID-19 status during the study period. No equals missing data, i.e. no information on COVID-19 status available. Yes equals, COVID +, COVID – or Unknown. In March only cases after 15/03/2020 were included.

Supplementary Figure 4: Distribution of age




Supplementary Figure 4: Distribution of age in relation to COVID-19 status.

Supplementary Figure 5: Etiology of IHCA, according to sex




Supplementary Figure 5A: Etiology of IHCA, men only.




Supplementary Figure 5B: Etiology of IHCA, women only.

Supplementary Figure 6: Conditions preceding IHCA, according to sex




Supplementary Figure 6A: Conditions preceding IHCA, men only.



Supplementary Figure 6B: Conditions preceding IHCA, women only.

Supplementary Figure 7: Cox adjusted survival curve for the overall population



Supplementary Figure 7: Cox adjusted survival curve for the overall population, stratified on COVID-19 status.

STROBE Statement—checklist of items that should be included in reports of observational studies

	Item No	Recommendation	Page No
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	1
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	2-3
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	2
Objectives	3	State specific objectives, including any prespecified hypotheses	2
Methods			
Study design	4	Present key elements of study design early in the paper	2
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	2
Participants	6	(a) <i>Cohort study</i> —Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up <i>Case-control study</i> —Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls <i>Cross-sectional study</i> —Give the eligibility criteria, and the sources and methods of selection of participants	2
		(b) <i>Cohort study</i> —For matched studies, give matching criteria and number of exposed and unexposed <i>Case-control study</i> —For matched studies, give matching criteria and the number of controls per case	2
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	5-6
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	5
Bias	9	Describe any efforts to address potential sources of bias	3-4
Study size	10	Explain how the study size was arrived at	5
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	5-6
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	6-7
		(b) Describe any methods used to examine subgroups and interactions	6-7
		(c) Explain how missing data were addressed	6-7
		(d) <i>Cohort study</i> —If applicable, explain how loss to follow-up was addressed <i>Case-control study</i> —If applicable, explain how matching of cases and controls was addressed <i>Cross-sectional study</i> —If applicable, describe analytical methods taking account of sampling strategy	6-7
		(e) Describe any sensitivity analyses	6-7

Continued on next page

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Results			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	7
		(b) Give reasons for non-participation at each stage	7
		(c) Consider use of a flow diagram	Supplementary material
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	7-8
		(b) Indicate number of participants with missing data for each variable of interest	7-8
		(c) <i>Cohort study</i> —Summarise follow-up time (eg, average and total amount)	7
Outcome data	15*	<i>Cohort study</i> —Report numbers of outcome events or summary measures over time	8-9
		<i>Case-control study</i> —Report numbers in each exposure category, or summary measures of exposure	
		<i>Cross-sectional study</i> —Report numbers of outcome events or summary measures	
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	7-10
		(b) Report category boundaries when continuous variables were categorized	
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	Supplementary material
Discussion			
Key results	18	Summarise key results with reference to study objectives	11
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	13-14
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	11-14
Generalisability	21	Discuss the generalisability (external validity) of the study results	14
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	14

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely

1
2 available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at
3 <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is
4 available at www.strobe-statement.org.
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only